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In the 21st century, diabetes mellitus (DM) emerged as one of the most prevalent non-communicable 
diseases and poses a major problem for every health system in the world. Its global prevalence has more 
than doubled in the last three decades. As diabetes has become more prevalent, the health 
programming designed to target diabetes patients has remained inadequate and only heightened the 
burden. This heightened burden has manifested itself in the increased risk of complications common 
among patients with diabetes. These complications vary widely, and are typically categorized as either 
micro-vascular or macro-vascular depending upon the size of blood vessels that are compromised. Due 
to the havoc that can ensue by either type of complication, the increased risk of diabetes-related 
complications has been recognized as a serious threat to population health.  
To gain insight into the threat posed and how it will likely present in the Canadian population, patient’s 
data from the diabetes component of Survey on Living with Chronic Diseases in Canada (SLCDC-DM-
2011) was analyzed. This analysis revealed that among Canadian diabetes patients, 80.26 percent 
reported having at least one type of diabetes-related complication. The most frequently reported 
complications were high blood pressure (54.65%), cataracts (29.52%), poor circulation (21.68%), and 
heart disease (19.4%). This analysis also revealed the predictive role of socio-economic factors 
associated with diabetes-related complications in Canada. Being married, having a higher income, and 
having a higher level of education were protective against most complications. In contrast, low levels of 
physical activity and high levels of HbA1C were important risk factors for many diabetes–related 
complications. Identifying common diabetes-related complications, protective factors and risk factors is 
useful for combating the threat posed by diabetes-related complications.  
To combat this threat in practice, healthcare professionals will play a significant role in the control and 
management of diabetes and its complications. Diabetes is a chronic disease that needs long-term 
treatment, and thus multi-disciplinary teams will be required. Increasingly, pharmacists are being 
determined as having a prominent position on these teams due to their accessibility to the Canadian 
population, and their expanding scope of practice. This profession has contributed positively to the long-
term prognosis of patients with diabetes, in part, by aiding in the control and management of the 
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disease. This aid oftentimes comes in the form of pharmacy-based interventions. Pharmacy-based 
interventions include a variety of services aimed at enabling patients with diabetes to have better 
control of their condition.  
I conducted a systematic review and meta-analysis to evaluate the effects of pharmacy-based 
interventions on clinical and non-clinical outcomes associated with diabetes-related complications. Four 
main databases were searched. Based upon my meta-analysis, the standardized absolute mean 
difference in reduction of HbA1C (%) from baseline to the time of the last follow-up significantly 
favoured patients in the pharmacy-based intervention group compared to those receiving care as usual 
(0.96%; 95% CI 0.71: 1.22, P<0.001). In addition, the standardized absolute mean difference in reduction 
of BMI unit (kg/m2) was 0.61 (95% CI 0.20: 1.03, P<0.001) in favour of the pharmacy-based intervention 
group. Both of these results demonstrate the positive effect pharmacy-based interventions can have on 
clinical outcomes. However, there is a dearth of evidence about the effects of pharmacy-based 
interventions on non-clinical outcomes, including health care utilization and quality of life. Therefore, it 
was not possible to evaluate non-clinical outcomes associated with diabetes-related complications in 
the same way.  
Each year healthcare expenses incurred from diabetes and its complications total more than US$827 
billion. This health care cost is significant, and is only expected to grow alongside diabetes’ increasing 
prevalence. In light of this, a debate over the comparative effectiveness of the different strategies used 
to manage diabetes and its complications has been sparked. The development of analytic models that 
can be used as tools in determining budget prioritization and cost-effectiveness of interventions is 
beginning to be prioritized. To conduct an economic evaluation of these interventions, simulation 
models are necessary. These models estimate health outcomes, such as life years saved or Quality 
Adjusted Life Years (QALYs) gained, and account for the costs and health consequences associated with 
diabetes, its complications and risk factors. 
I developed a hybrid (agent-based/system dynamic) individual-level micro simulation model using 2,931 
patient records from the SLCDC-2011. This model extrapolated the effects of pharmacy-based 
interventions on health outcomes, costs and health-related quality of life (HRQOL) over time through 
time-varying risk factors of diabetes-related complications. The treatment effects of pharmacy-based 
interventions were modeled as reductions in HbA1c levels, BMI, systolic blood pressure and LDL, all of 
which can affect the risk of progressing long-term complications. The annual costs of diabetes-related 
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complications, as well as, costs associated with pharmacy-based intervention from a societal 
prospective, were also considered. Using this data, the micro-simulation model was able to estimate the 
expected number of major health events (heart failure, stroke, amputation, and blindness), QALYs over 
a patient’s lifetime, the patient’s economic burden on the health care system, and the extent to which 
pharmacy-based intervention can modify these outcomes. Deterministic and probabilistic sensitivity 
analyses were conducted to evaluate the uncertainty around the results. 
Based on the results from my micro-simulation model, a pharmacy–based intervention could avert a 
total of 155 deaths associated with complications, 19 heart failures, 159 strokes, 24 amputations and 29 
blindness events in a population of 2,931 patients over the next 50 years. In addition, the intervention 
could add 1,246 additional life-years (0.42 per patients) and 953 additional quality-adjusted life-years 
(0.32 per patients). The intervention would also be cost-effective in comparison to usual care, as 
indicated by the incremental discounted cost per QALY gained ($3928). Overall, these results suggest 
that an integrated pharmacy-based intervention could be a cost-effective strategy to control and 
manage diabetes-related complications in Canada. This is promising and has important public health 
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1.1. Overview and Rationale  
1.1.1. Determinants of Diabetes Complications and its Burden 
Diabetes mellitus (DM) is one of the most prevalent non-communicable diseases worldwide, and poses a 
major threat to the 21st century health care system (1, 2). Perhaps most threatening about DM is its 
unprecedented growth: In less than three decades, the number of adults diagnosed with diabetes has 
doubled (2). This translates to over 400 million people living with diabetes today, and an estimated 642 
million who will live with diabetes by 2040(3). According to the Canadian Diabetes Association, 29 
percent of Canadians are currently living with pre-diabetes or diabetes, and if current trends continue, 
this percentage will increase to 33 percent by 2025(4). In 2016 alone, the number of new cases of 
diabetes among Canadians was 347.8 per 100,000. These 348 Canadians will experience a total of 
798.53 Disability Adjusted Life Years (DALYs) amongst themselves (5). This epidemiologic trend raises 
significant concern, especially when compared to the global incidence trend of diabetes (Figure 1). 
Unsurprisingly, typical complications that develop alongside diabetes are more common among patients 
with diabetes than in the general population. Almost 89 percent or 9 out of 10 patients with diabetes 
report adverse health effects that are related to their condition (2). These complications vary widely, 
and are typically categorized as either micro-vascular or macro-vascular. Conditions that damage the 
body’s smaller blood vessels, like retinopathy, neuropathy, and nephropathy, are categorized as micro-
vascular (6-8). In contrast, conditions that result from damage to the body’s larger blood vessels, like 
cardiovascular disease, are categorized as macro-vascular (6-8). Irrespective of the complications’ 
categorization, patients with diabetes place a significant burden on the health care system. This burden 
is a result of both direct and indirect strains placed on healthcare services, family dynamics, and 
government (3).  
In light of these strains and their effects on the Canadian health care system, a number of risk factors of 
diabetes-related complications have been recognized. For example, hemoglobin A1C (HbA1C) is 
universally accepted as a measurement of long-term blood glucose control. In clinical trials, lower levels 
of HbA1C reduced the likelihood of developing microvascular complications over the short-term, and 
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macrovascular complications over the long-term (9, 10). Importantly, some of these risk factors can be 
modified through lifestyle interventions. One such risk factor is obesity; an increased body mass index 
(BMI) is associated with the development of type 2 diabetes, diabetes-related complications or both (11, 
12). Smoking has also been linked to the development of diabetes-related complications; Cigarette 
smoking increases the risk of some of the most serious complications, including cardiovascular disease, 
kidney disease, and neuropathy (13). Metabolic variables such as total cholesterol, triglycerides levels, 
and FPG have also been found to be positively associated with diabetes-related complications (15, 16). 
Similarly, age of onset and duration also share positive relationships with the development of diabetes-
related complications (16-18). Identification of these risk factors means that prevention and 
management strategies can be developed to minimize their impact (14). Despite the ability to design 
prevention and management strategies that are specific to these factors, there is a dearth of literature 
examining the relationships between Canadian patient characteristics and diabetes-related 
complications. 
1.1.2. Pharmacy Practice and Diabetes Care 
When diabetes is diagnosed at an advanced stage, the burden that results is heightened. Unfortunately, 
diabetes management interventions are rarely promoted and there are limited interventions available 
that empower diabetes patients to effectively control and manage their condition. Again, this only 
heightens the resulting burden. However, if preventive strategies were introduced at the pre-diabetes 
or early diabetes change, this burden could be reduced (19). For example, half (50%) of type 2 diabetes 
cases could be delayed or prevented altogether if those patients followed a healthy eating plan and 
increased their physical activity (20). Further, when multi-factorial interventions are adopted, the 
number of diabetes-related complications and deaths resulting from diabetes are reduced by nearly 60 
percent (20). In this vein, there are some community programs available. However, it is evident that 
more could be done to prevent or, at the very least, delay diabetes-related complications through the 
implementation of comprehensive prevention strategies.  
Much of the literature to date suggests that comprehensive prevention strategies positively impact 
metabolic outcomes through the control and management of major risk factors, and, ultimately, reduce 
diabetes-related complications among various patient groups. Examples of these strategies include self-
monitoring and self-management at the individual level, and pharmacy-based programming at the 
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community level. Self-monitoring and self-management have been shown to be associated with 
clinically important benefits in persons with diabetes (21-23), such as improved QOL, sustained weight 
loss, and increased cardiovascular fitness (23). Further, a random-effect modelling estimated the pooled 
mean difference in HbA1C between patients undertaking self-care management and patients in a 
control group to be 0.36% (0.20-0.50) (15). Thus, there is evidence pointing to the positive impact of 
comprehensive prevention strategies in the control and management of diabetes, and these strategies 
must be incorporated into practice.    
Incorporation of comprehensive management strategies into practice will require cooperation and 
collaboration across multi-disciplinary health care teams. Diabetes is a chronic disease, and thus 
requires treatment over a long-time period. Consequently, an interdisciplinary team of healthcare 
professionals is required and each professional plays a pivotal role in contributing to patients’ diabetes 
control and management (24). Increasingly, pharmacists are being recognized because of their 
accessibility to patients and expanding scope of practice. Only by ensuring that pharmacists can 
positively contribute to the long-term prognosis of diabetes patients will improvements in the control 
and management of diabetes is realized (25).    
Pharmacy-based interventions include a wide range of services, all with the common aim of giving 
diabetes patients greater control and management over their disease. Common examples of pharmacy-
based interventions include: consultations with pharmacists; patient education about self-monitoring 
and self-management techniques; preventive programming that emphasizes lifestyle modifications; 
reminders about annual physical examinations; assistance with adherence to medication; patient 
education about the correct use of insulin, anti-hyperglycemic medications and oral hypoglycemic 
agents; and, programming that increases patients’ awareness about effective diabetes management 
(25-29). Recent reviews of pharmacy-based interventions have demonstrated that they have a positive 
impact on clinical outcomes (25-29). These findings are promising, especially because they suggest that 
pharmacy-based intervention may reduce diabetes-related complications, morbidity and mortality (25-
29). However, before pharmacy-based interventions should be adopted as the best practice by health 
professionals, the clinical and non-clinical effectiveness of these interventions in the control and 
management of diabetes-related complications must be examined.  
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1.1.3. Economic Evaluation of Pharmacy-Based Interventions 
Diabetes-related complications lead to premature death, reduce individuals’ quality of life, and place a 
heavy economic burden on the whole of society to the tune of US$548 billion each year (3, 30-33). This 
cost is not limited to the health care system, but also includes indirect costs incurred by loss of 
productivity resulting from disability and/or premature death (34). Unfortunately, the prognosis in 
Canada is not much better. According to the Canadian Diabetes Cost Model, 2.7 million people have 
diabetes in 2010. This number is projected to increase by 1.5 million over this decade, and will reach 4.2 
million by 2020 (2). In addition, the economic burden of diabetes in Canada was an estimated $12.2 
billion in 2010, and is forecasted to increase to $16 billion by 2020 (3). 
Comparing  to the general population, diabetes patients are: twenty times more likely to be admitted to 
the hospital for an amputation of the lower limb; also twelve times and three times more likely to be 
admitted to the hospital for end-stage renal disease and cardiovascular disease respectively    (14,35). 
This means that, of the Canadian healthcare dollars being expended on diabetes patients, eighty percent 
are incurred as a result of diabetes-related complications (36). The increased likelihood of requiring 
hospitalization may reflect these patients’ inability to adhere to treatment plans as prescribed as a result 
of the high cost of medications, devices, and supplies that are frequently paid for out-of-pocket, for 
example (37). 
Accommodating the increasing demand for accessible and reasonable health care services within 
budgetary constraints has forced Canada’s decision-makers to find new ways to program, implement, 
and evaluate health services. In light of this, pharmacists are emerging as a potential avenue to improve 
health outcomes, as well as reducing the economic burden of health care. Although pharmacists’ roles 
are expanding across the country, different approaches taken by provincial and territorial governments 
mean these roles are nuanced.  Nevertheless, pharmacists are providing a larger complement of services 
targeting minor issues to complicated chronic conditions. This profession is undergoing a 
transformation, yet the literature describing pharmacists’ changing role in the broader healthcare 
system is not well-articulated. Specifically, attention must be paid to economic analyses, especially 
because they oftentimes inform policymakers’ decisions (38). 
Rising health care costs, limitations on available health care resources, and debates over the 
comparative effectiveness of diabetes management strategies has led to an increased interest in 
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developing analytic models that can predict cost-effectiveness. These models complement clinical trials, 
which typically run over the short-term and provide data on intermediate outcomes like HbA1c, SBP, 
and LDL. This data populates analytic models, and provides a basis for predicting long-term health 
outcomes, like life-years saved or QALYs gained. The ability to account for costs and health 
consequences associated with risk factors add to the appeal of using these models to inform health 
practices and policies (38). Assessing the cost effectiveness of Pharmacy-based interventions will 
provide evidence for policy-maker about whether expanding these community-based interventions for 
diabetics’ population across Canada is cost-effective or not. 
1.2. Goals and objectives of the research 
 
The purpose of this thesis is to examine diabetes-related complications in Canada. The study will address 
three principal research questions: 
1) How prevalent are diabetes-related complications in Canada, and what determinants are 
associated with them?  
2) What is the current state of evidence on the clinical effectiveness of pharmacy-based 
interventions in the control and management of diabetes? 
3) What is the predicted effect of pharmacy-based interventions on reducing diabetes-related 
complications, especially in terms of their economic burden?  
 
To answer each of these questions, this thesis has been organised into a series of three chapters.  
 
Paper 1, presented in Chapter 2, used patients’ data collected in the Survey on Living with Chronic 
Diseases in Canada (SLCDC) to provide a description of epidemiological trends and characteristics 
present among Canadian diabetes patients. We also examined the association between diabetes-related 
complications and select determinants.  
 
Paper 2, presented in Chapter 3, describes the results of our systematic review and meta-analysis that 
evaluated the effects of pharmacy-based interventions on clinical outcomes associated with diabetes-




Paper 3, presented in Chapter 4, describe our individual patient micro-simulation model that we 
developed to estimate the incidence and mortality of four of the most common diabetes-related 
complications (heart failure, stroke, amputation, and blindness). We used risk equations based on the 
UK Prospective Diabetes Study (UKPDS). Based on the estimated effect of pharmacy-based interventions 
on reducing time-varying risk factors for diabetes-related complications, we extrapolated the potential 
effects of pharmacy-based interventions in relation to cost, health outcomes, and health-related quality 
of life (HRQoL) over time (Chapter 4). 
 
The paper presented in Chapter 3 has been published in a peer-reviewed journal as “Yaghoubi M, 
Mansell K, Vatanparastc H, Steeves M, Zeng W, Farag M. Effects of pharmacy-based interventions on the 
control and management of diabetes in adults: a systematic review and meta-analysis. Can J Diabetes. 
2017 Dec; 41(6):628-641. doi: 10.1016/j.jcjd.2017.09.014.”. The permissions to include the reformatted 
paper in this thesis are included in Appendix A-1. 
 
This thesis was deemed to be exempt from ethical review by the University of Saskatchewan Research 
Ethics Board (REB) based on Article 2.2 of Tri-Council Policy Statement on Ethical Conduct for Research 
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CHAPTER 2-PREVALENCE OF DIABETES-RELATED COMPLICATIONS AND THEIR ASSOCIATION 
WITH DETERMINANTS IDENTIFIED IN CANADA’S SURVEY ON LIVING WITH CHRONIC DISEASES 
 
This article has been submitted as: “Yaghoubi M, Mansell K, Vatanparast H, Steeves M, Zeng W, Farag 
M. Prevalence of diabetes-related complications and their association with determinants identified in 
Canada’s Survey on Living with Chronic Diseases – Diabetes Component (SLCDC-DM-2011” for 
publication in a peer-reviewed journal. My contributions to this manuscript included conceiving and 
designing the study, running the all statistical analysis, interpreting the findings and manuscript 
preparation. Dr. Marwa Farag and Dr. Hassan Vatanparast helped in conception and design of the study. 
All authors helped in the interpretation of findings and in reviewing and editing the manuscript.  
 
Analyzing the current epidemiological trends of diabetes-related complications is very important for 
public health policy makers in Canada hoping to reduce the burden of these complications. In this 
chapter, I describe the epidemiological trends and characteristics present among Canadians who have 
diabetes.  I also use a multiple logistic regression to identify the most important risk factors associated 
with diabetes-related complications in Canada. The results of this chapter have been used to design the 

















Globally, the prevalence of diabetes has more than doubled from 1980 to 2014 (from 4.7% to 8.5%) (1). 
This increased prevalence has also come with an increasingly high burden, which is partially due to 
inadequate health programming targeted specifically towards patients with diabetes, amongst other 
factors(2). Correspondingly, patients with diabetes are at an increased risk of experiencing 
complications related to their diagnosis, and this risk has been recognized as a serious threat to 
population health (3). These complications are typically categorized as either micro-vascular or macro-
vascular complications (4-6).  
The financial implications of diabetes-related complications are significant (1)(7). In light of this cost, the 
association between diabetes-related complications and various patient characteristics has been 
investigated extensively. Results from the multinational A1chieve study; observational study of 66,726 
people with type 2 diabetes in 28 countries across Asia, Africa, Europe and South America; showed that 
the prevalence of micro-vascular diabetes-related complications was 27.2 percent in 2004, and the 
prevalence of macro-vascular complications was almost double at 53.3 percent(8). Patients’ age, body 
mass index (BMI), and the duration of diabetes were all strongly positively associated with the 
development of both types of complications (8). However, patients were at a lower risk of developing 
micro vascular complications when they had a low level of A1C or glucose in their blood (8). Factors 
associated with diabetes-related complications in Canada have been examined for some specific 
complications including; visual impairment, erectile dysfunction, cardiovascular complications, and 
cognitive impairment (9-12). In addition; Hanley et al (13) evaluated risk factor associated with 
complications of type 2 diabetes among aboriginal Canadians in the Sandy Lake Diabetes Complications 
Study. 
The aim of this study is to examine the association between diabetes-related complications and select 
determinants of Canadian patients, to provide a description of epidemiological trends and 





2.2. Data and methods 
 
Data from the 2011 Survey on Living with Chronic Disease in Canada –Diabetes Component (SLCDC-DM-
2011) was used. The SLCDC is a cross-sectional survey that collects the wide range of information about 
chronic disease in Canadian population. In this survey respondents answered questions about diagnosis 
of chronic condition, health care utilization and self-monitoring and self-management of their 
conditions. The SLCDC aimed to provide information on the impact of chronic disease condition on 
population, as well as how people with chronic disease control their health condition (14). 
The inclusion criteria of participants specified that: individuals must be above the age of 20 years; must 
have self-reported having diabetes on the 2010 Canadian Community Health Survey (CCHS); and, 
consented to participate in the SLCDC-DM-2011(14).Members of the Canadian Armed Forces, 
institutionalized individuals, residents of First Nation reserves or Crown Land, and residents of Canada’s 
three territories were excluded (14). To ensure the survey sample was representative of the Canadian 
population eligible for inclusion, the sample was weighted according to Statistics Canada’s instructions 
(14). With weighting applied, 1,711,743 participants are represented based on 2,931 survey responses. 
2.2.1.Dependent variables 
In this analysis we have measured the association between diabetes-related complications as dependent 
variables and select determinants of Canadian patients including: socio-demographic factors, diabetes 
status, risk factors, and self-monitoring behaviour as independent variables. The SLCDC-DM-2011 asked 
participants, “Whether (they had) ever had ‘specific complication’ diagnosed by a health professional?” 
Sixteen different diabetes-related complications were specified in the above line of questioning. We 
categorized these sixteen complications into groups to create dependent variables in the three logistic 
regression models: (1) all diabetes-related complications; (2) micro-vascular complications; and (3) 
macro-vascular complications. Participants were considered to be a member of group 1 if they reported 
having had at least one of the sixteen diabetes-related complications specified on the SLCDC-DM-2011. 
Participants were considered to be a member of group 2 if they reported having had at least one of the 
following complications: neuropathy, retinopathy, cataracts, glaucoma, kidney failure, foot ulcer, poor 
circulation in the feet or legs, protein in urine, amputation, and/or blindness. Participants were 
considered to be a member of group 3 if they reported having had at least one of the following 
complications: heart disease or stroke. 
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2.2.2. Independent variables  
Based on a thorough review of the literature, independent variables considered to be potential 
determinants of diabetes-related complications for Canadian patients were selected 
(8)(9)(10)(15)(16)(17).  Each of the selected determinants were classified into one of four categories:(1) 
socio-demographic factors (sex, age, employment status, marital status, income level, and education); 
(2) diabetes status (type of diabetes, years with diabetes, injection of insulin);(3) risk factors (BMI, 
frequency of smoking, physical activity level, level of A1C);and (4) self-monitoring behaviour (frequency 
of checking blood glucose level).Justification and a detailed description of each independent variable is 
provided below.  
2.2.2.1. Socio-demographic  
Much of the literature highlights the importance of socio-demographic factors and their link with the 
appearance of diabetes-related complications among patients with diabetes. Factors that have been 
found to be associated with the diabetes-related complications include: an older age of onset 
(8)(10)(12)(15)(16); a patient’s sex (8)(9); being unmarried (9)(15)(17); and a patient’s socioeconomic 
status categorized by their level of education, income, and employment(18)(19). Based on this literature 
and within the confines of the SLCDC-DM-2011, the socio-demographic factors in this study were 
defined as follows: age (20-45 years, 45-70 years, and >70 years); sex (male or female); marital status 
(married, common-law, widowed, separated, divorced, and single); education (less than secondary 
school, secondary school, some post-secondary school, and post-secondary school); income (less than 
$50,000 per annum or more than $50,000  per annum); and, employment  status (had a job, did not 
have a job, and unable to work). 
2.2.2.2. Diabetes status  
Three main sources that cause significant differences in patient health outcomes have been identified. 
These differences include: whether a patient has a diagnosis of type I or type II diabetes (20); the period 
of time that a patient has had diabetes,(21); and, the mode of treatments (22)(28).Therefore, in the 
present study diabetes status was defined in the following ways: diabetes status (type I or type II); years 
with diabetes (less than 10 years or more than 10 years); and, injection of insulin (yes or no).  
2.2.2.3. Risk factors 
Individuals are at increased risk of developing diabetes and experiencing diabetes-related complications 
if they are overweight or obese (15)(23)(24),  smoke cigarettes ,engage in low levels of physical 
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activity,(24) and have a high level blood sugar(25). To quantify these risk factors in the present study, 
the following variables were used: BMI (range 18.5-25 kg/m2 as normal or and under 18.5 or over 25 
kg/m2 as inappropriate); frequency of smoking (daily, occasional, former daily, former occasional, and 
never); physical activity level (active, moderate, and inactive); and, level of A1C (well, borderline, high, 
low). 
2.2.2.4. Self-monitoring behaviour 
When comparing disease-related morbidity and mortality between patients who self-monitor their 
blood glucose and those who do not, there are mixed results; thus, a self-monitoring variable was 
included in the present study as follows: frequency of checking blood glucose (per day, per week, per 
month, per year, and never).  
2.2.3. Statistical analysis  
Logistic regression models were used and fitted for each one of the three dependent variables. 
Additionally, sixteen logistic regression models were constructed individually for each diabetes-related 
complication included on the SLCDC-DM-2011. 
Final logistic regression models were fitted by purposeful model selection. A standard contingency table 
was created for each categorical independent variable to determine if the cell frequency was equal to 
zero for any of the model outcomes. The association between diabetes-related complications and select 
determinants was then measured using odds ratios. In addition, the prevalence of each diabetes-related 
complication was calculated with a 95% confidence internal (Table 2.1).  
All statistical analyses were performed using version 14 of STATA (StataCorp LLC, TX). First, bivariable 
analysis was conducted to test the association between each dependent variable and each independent 
variable. In this analysis, a significance value of 0.25 was used to: (1) adjust for the multiple comparisons 
being made and (2) rule out variables that would not contribute meaningfully to the multivariable  
analysis. Full results of the bivariable analysis are presented in Table 2.2 and Table 2.3. 
Second, a multivariable  regression analysis was conducted for each of the three grouped dependent 
variables: all diabetes-related complications, micro-vascular complications, and macro-vascular 
complications. The multicolinearity and interaction terms of each independent variable were tested and 
no multicolinearity or interaction terms were found. A p-value<0.05 was used to identify significant 
associations between the dependent and independent variables in these models. Additionally, the 
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goodness of fit was assessed using the Hosmer and Lemeshow tests from which it was determined that 
each model fit the data well. From these tests, the p-value of the all diabetes-related complications 
model was 0.86, the p-value of the micro-vascular complications model was 0.28, and the p-value for 
the macro-vascular complications model was 0.99. The Linktest was also used to examine model 
specifications, and yielded 0.98, 0.76, and 0.67 for each model respectively. These values indicate that 
there was no specification error in any of the study’s models. Lastly, a multivariable  regression model 
was constructed for each individual diabetes-related complication included on the SLCDC-DM-2011 as 
part of this study’s sub-group analysis. All statistical tests mentioned previously were also performed in 
this sub-group analysis 
2.3.Results 
With weighting applied, there were a total of 1,711,743 Canadian participants who self-reported having 
diabetes on the SLCDC-DM-2011. Among them, 1,373,887 or 80.26 percent reported having at least one 
type of diabetes-related complication. The most commonly reported diabetes related complication was 
high blood pressure (54.65%, CI: 51.28-58.02). Other common diabetes-related complications included: 
cataracts (29.52%, CI: 26.71-32.32); poor circulation (21.68%, CI: 19.01-24.36); heart disease (19.40%, CI: 
16.9-21.8); protein in the urine (14.65%, CI: 11.66-17.63), and erectile dysfunction (14.60%, CI: 12.42-
16.92) (Table 2.1). More broadly, micro-vascular complications (50.93%, CI: 47.58-54.27) were twice as 













Table 2.1. Prevalence of diabetes-related complication in SLCDC-DM-2011 
 
Complication  Type Prevalence  
Low blood sugar (Hypoglycemia)  2.45% (1.30-3.61)  
Erectile Dysfunction  14.6% (12.42-16.92) 
Problem with Gum (periodontal Disease)  7.54% (5.88-9.20) 
High Blood Pressure  54.65% (51.28-58.02) 
Neuropathy Microvascular 10.2% (8.20-12.29) 50.93% (47.58-54.27) 
Diabetic eye disease (retinopathy) Microvascular 6.88% (5.32-8.43) 
Cataract Microvascular 29.52% (26.71-32.32) 
Glaucoma Microvascular 7.13% (5.65-8.60) 
Kidney failure Microvascular 5.09% (3.09-7.08) 
Foot ulcer Microvascular 6.13% (4.22-8.04) 
Poor Circulation Microvascular 21.68% (19.01-24.36) 
Protein in urine (Proteinuria) Microvascular 14.65% (11.66-17.63) 
Amputation Microvascular 0.48% (0.03-0.10) 
Blindness Microvascular 1.83% (0.90-2.74) 
Stroke Macrovascular 7.70% (5.64-9.76) 23.66% (20.86-26.47) 
Heart disease Macrovascular 19.4% (16.9-21.8) 
 
2.3.1.Bivariable analysis 
Diabetes-related complications occurred most frequently among patients: aged 45-70 years (47.75%); 
who were males (46.11%); diagnosed with type II diabetes (64.40%); reporting inappropriately on the 
BMI index (73.38%), inactive on physical activity index (53.28%); and checking blood glucose levels daily 
(47.34%) (Table2.2).Bivariable analysis revealed significant associations between all determinants and 
diabetes-related complications with a few exceptions. In the all diabetes-related complication model, 
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type of diabetes and sex were not significantly associated with the outcome variable (Table 2.2). In the 
macro-vascular and micro-vascular complication model, BMI was not significantly associated with the 
outcome variable (Table 2.3). Results of the bivariable analysis are shown in Table 2.2 and Table 2.3. All 























Table 2.2. Bivariable analysis and characteristics of patients with diabetes-related complication 
 
Characteristics (%) No Complication n (%) 
N=337,856 
19.74% 
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Had a Job (36.8) 
Did not have a job (38.7) 
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Diabetes Status Factors 
Type of Diabetes 
Type 1 (8.22) 

















Duration of Diabetes     
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Less than 10 Years (53.58) 
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Checking Blood sugar 
Per day (55.55) 
Per week (25.47) 
Per month (5.84) 




























Table 2.3 Bivariable logistic regression by Micro-vascular and Macro-vascular complications 
Variables  Model (2) 
Microvascular (Yes vs. No) 
Model (3) 
Macrovascular (Yes vs. No) 
 OR CI P OR CI P 
Age 
20-45 Years  
45-70 Years  




































































































Had a job 
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Type of Diabetes 
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Never  0.93 (0.61-1.42) 0.76 0.70 (0.43-1.14) 0.16 
































































Checking Blood sugar 
Per day 
Per week  
Per month  

































2.3.2.Multivariable  analysis by grouped diabetes-related complications 
 
Result from multivariable analysis in three models in terms of three different dependent variable are 
shown in Table 2.4 
Socio-Demographic Factors: The multivariable analysis reveals that people over the age of 70 years 
were 4.88 times more likely to report having a diabetes-related complication than people aged 20 to 45 
years. This group was also 5.58 and 3.37 times more likely to report having a micro-vascular 
complication and a macro-vascular complication respectively than their younger counterparts. Female 
patients were 0.56 times less likely to report having a macro-vascular complication than male patients. 
Widowed patients were about twice as likely to report having a diabetes-related complication than 
married patients (OR=1.98), and were also roughly twice as likely to occurrence a micro-vascular 
complication (OR=2.02). Similarly, patients who did not have a job experienced an increased likelihood 
of having had both a micro-vascular (OR=1.70) and macro-vascular (OR=1.67) complication compared to 
their working counterparts. A complementary trend was revealed when analyzing income: that is, 
patients in the higher income category were less likely to report both micro-vascular (OR=0.67) and 
macro-vascular (OR=0.64) complications. 
Diabetes Status; Patients with type II diabetes were less likely to have micro-vascular complications 
(OR=0.51) compared to patients with type I diabetes. There was no significant association between a 
patient’s type of diabetes and the likelihood of developing a macro-vascular complication or any 
diabetes-related complication. The multivariable  analysis also revealed that patients who had diabetes 
for more than 10 years were approximately double as likely to report having any diabetes-related 
complication (OR=2.20), a micro-vascular complication (OR=2.07), or a macro-vascular complication 
(OR=1.61) compared to those who had diabetes for less than 10 years. Patients who injected insulin 
were also at an increased risk of developing diabetes-related complications: that is, patients were 0.58 
times more likely to report any diabetes-related complication and 1.05 times more likely to report a 
micro-vascular complication than patients who did not inject insulin.  
Risk Factors; having an inappropriate BMI was found to be positively associated with having any 
diabetes-related complication in comparison to those with a normal BMI (OR=2.15). Compared to 
current daily smokers, patients who report currently smoke occasionally had a lower likelihood of having 
a micro-vascular complication (OR=0.23). Patients who were inactive were twice as likely to report 
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having macro-vascular complications compared to those who had active (OR=2.46). Patients who 
reported a having a high level of A1C were also more likely to report having a macro-vascular 
complication compared to patients with a well level of A1C (OR=1.88). 
Self-Monitoring Behaviours; No significant associations were found between diabetes-related 
complications, micro-vascular complications, or macro-vascular complications and self-monitoring 
variables. Complete results for self-monitoring behaviour are presented in Table 2.4. 
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Table 2.4. Multivariable logistic regression of all diabetes-related complications, micro-vascular complications, and macro-vascular 
complications 
Variables  Model 1 
All Complication (Yes vs. No)  
Model 2 
Microvascular (Yes vs. No) 
Model 3 
Macrovascular (Yes vs. No) 
 OR CI P OR CI P OR CI P 
Age 
20-45 Years  
45-70 Years  
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Did not have a job  
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Post graduate  0.75 (0.38-1.47) 0.40 1.82 (1.01-3.30) 0.04 0.74 (0.41-1.32) 0.31 
Type of Diabetes 
Type 1 




























Duration of Diabetes  
Less than 10 years 


















































































































































































































































Checking Blood sugar 
Per day 
Per week  







































Per year or never  0.59 (0.29-1.21) 0.15 0.76 (0.38-1.53) 0.45 1.95 (0.90-4.19) 0.08 
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2.3.3.Multivariable  analysis by individual diabetes-related complications  
All significant associations between each diabetes-related complication reported in the SLCDC-DM-2011 
and the study’s independent variables are presented in Table 2.5. Select results will be presented and 
discussed here by diabetes-related complication. Also, detail results of multivariable analysis by each 
complication are shown in Appendix B.  
Hypoglycemia; Both level of physical activity and A1C level were found to be important risk factors for 
hypoglycemia. Those who were inactive and who had a high A1Clevel were 6.75 times and 4.60 times 
more likely to report hypoglycemia compared to active patients and those with well A1C levels.  
Periodontal Disease; Females were more likely to report having problems with their gums or 
periodontal disease compared with males (OR=1.67). Being unemployed (OR=2.52), injecting insulin 
(OR=2.52), and having a high level of A1C (OR=2.03) were also positively associated with this 
complication.  
Erectile Dysfunction; Patients with an inappropriate BMI were more than twice (OR=2.08) as likely to 
report having erectile dysfunction as a result of their diabetes. Other factors positively associated with 
erectile dysfunction include high levels of A1C (OR=2.41), older age (OR=5.12), longer duration of 
diabetes (OR=1.56), and injecting insulin (OR=2.26). Patients who had never smoked were 0.51 less likely 
to report this complication compared to patients who smoked daily.    
High Blood Pressure; Patients with an inappropriate BMI were twice as likely to have high blood 
pressure (OR=2.84). Females were also more likely to have high blood pressure compared with male 
patients (OR= 1.46). Other determinants found to be predictive of high blood pressure include: older age 
(OR=2.05), longer duration of diabetes (OR=1.44), and unemployment (OR=1.62).  
Neuropathy; Patients who were separated from their partners were 4.60 times more likely to report 
having neuropathy compared to married patients. Being unemployed (OR=2.75) and injecting insulin 
(OR=2.60) were also found to be positively associated with having neuropathy as a result of one’s 
diabetes. Females were 0.54 times less likely to have this complication compared to their male 
counterparts.  
Retinopathy; A few determinants were strongly associated with retinopathy including: having diabetes 
for more than 10 years (OR=8.00); being over the age of 70 years (OR=3.30); and, injecting insulin 
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(OR=11.34). Former occasional smokers were 0.34 times less likely to report having retinopathy than 
daily smokers.   
Cataracts; having cataracts was associated with: being female (OR=1.89); not having a job (OR=4.02); 
having diabetes for more than 10 years (OR=2.89); being moderately active (OR =1.86); and, injecting 
insulin (OR =1.70). 
Glaucoma; Patients aged 45 to 70 years or older than 70 were 3.30 and 6.57 times more likely to have 
glaucoma respectively compared to patients aged 20 to 45 years. Having glaucoma was also positively 
associated with having diabetes for more than 10 years (OR= 1.69). 
Kidney Failure; Kidney failure was strongly associated with the ‘separated’ marital status (OR=5.11). 
Also, female less likely to report this complication compared with males (OR=0.33). Patients who had 
more annual income also less likely to report kidney failure (OR=0.24) 
Foot Ulcer; Patients who report being inactive or injecting insulin were roughly twice as likely to report 
having a foot ulcer as a result of their diabetes (OR=2.08 and OR=2.47). 
Poor Circulation; Patients who report being inactive or injecting insulin were roughly twice as likely to 
having poor circulation as a result of their diabetes (OR=2.05 and OR=2.27).  
Protein in Urine; Patients with high levels of A1C were more than twice as likely to have protein in their 
urine (OR=2.61).  
Heart Disease; Heart disease was more likely among patients who have high levels of A1C (OR=1.65); 
are physical inactive (OR=2.23); have more than a 10-year duration of diabetes (OR=1.79); and, inject 
insulin (OR =1.53). 
Stroke; A strong positive association was observed between stroke and both physical inactivity (OR= 
2.52) and high levels of A1C (OR=2.24).  
For each diabetes-related complication, every determinant that was found to be significantly associated 
with it is presented in Table 2.4. Because only 1.83 percent and 0.48 percent of SLCDC-DM-2011 
participants reported experiencing blindness and amputation respectively, when logistic regression was 
performed on these complications it was determined that they did not fit the data well. 
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Table 2.5. Significant factors in multivariable logistic regression by each complication 
Complications   OR                                    Value-P 
Low blood sugar (Hypoglycemia)   
Physical activity (Inactive) 











Erectile Dysfunction   
Age (45-70 Year) 
Duration (More than 10 Year) 



















Problem with Gum (Periodontal Disease)   
Sex (Female) 













High Blood Pressure   
Age (45-70 Year) 
Sex (Female)  
Employment (Did not have a job) 
Education (Post) 













Duration (>10 Years) 












Neuropathy   
Sex (Female) 
Marital Status (Separated)  
Employment (Did not have a job) 
Insulin (Yes) 
 














               0.02 
Retinopathy   
Age (70 or more)  
Marital Status (Divorced) 
Employment (Did not have a job) 
Income (More than 50K) 
Duration (>10 Years) 
















Cataract   
Age (70 or more)  
Sex (Female) 
Marital Status (Widowed) 
Employment (Did not have a job) 













Physical activity (Moderate) 
Insulin (Yes) 








Glaucoma   
Age 
45-70 Year 
70 or more Year 
Income (More than 50K) 











Kidney failure   
Sex (Female) 
Marital Status (Separated)  
Income (More than 50K) 












Foot ulcer   
Employment (Unable to work) 
Income (More than 50K) 















Employment (Unable to work) 










Proteinuria   
Age (45-70 Year) 














Stroke   
Employment (Did not have a job) 
Physical activity (Inactive) 










Heart disease   
Age (45-70 Year) 
Sex (Female) 
Income (More than $50,000) 
Education (Some-post) 
Duration (>10 Years) 
























                 





The present study aimed to estimate the prevalence of diabetes-related complications identified on the 
SLCDC-DM-2011 and identify associations between these complications and select determinants. 
Overall, our findings indicate that in Canada, the majority of diabetes patients experience complications, 
with high blood pressure, cataracts, poor circulation in the feet or legs, and heart disease being among 
the most common. Patients were more likely to have at least one complication when they were older, 
had diabetes for more than 10 years, were unemployed, had an inappropriate BMI, and had a high level 
of HbA1c. Other determinants, including sex, marital status, education, income, and physical activity, 
were also found to be significantly associated with micro-vascular and macro-vascular diabetes-related 
complications. The findings will be discussed in detail below by determinant category.  
Socio-Demographic Factors  
Analysis of Canadian diabetic patients’ age yielded a strong positive trend across all models. That is, as 
age increased the odds of having any diabetes-related complications, micro-vascular complications, and 
macro-vascular complications increased. Increasing age was also strongly associated with most of the 
diabetes-related complications when analyzed individually. Findings from the present study support and 
extend the work of others who have found that an older age of onset is associated with diabetes-related 
complications (8)(16)(26). For example, diabetic patients in Australia over the age of 80 were 12.42 (CI: 
1.26-121.85) times more likely to have retinopathy as a result of their diabetes (15).  Similarly, diabetic 
patients in Canada over the age of 80 were 18.12 (CI: 6.63-49.51) times more likely to have visual 
impairments as a result of their diabetes (9). Although these likelihoods are stronger than what was 
found in the present study, differing age cut-offs may explain the differences in strength. Importantly, 
the overall trends implicating age as a predictive factor of numerous diabetes-related complications 
remains consistent. Age may be a predictive factor of diabetes-related complications because continuity 
of care among older adults is often poor, and older adults are more likely to have other medical 
conditions that complicate their health status (27).  
Comparison of males and females reveals a number of sex differences in diabetes-related complications. 
Overall, females were less likely to have macro-vascular complications, and were also less likely to have 
neuropathy, kidney failure, and heart disease. However, females had a higher chance of having certain 
complications including retinopathy, cataracts, high blood pressure, and periodontal disease. 
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Differences in diabetes-related complications between the sexes have been found in previous 
examinations of Canadian diabetic patients and are consistent with the present study. When considering 
diabetes-related complications, the consistency with which sex differences have been documented 
indicates that genetic, lifestyle, environmental, or other socioeconomic factors that are known to affect 
the sexes differently may be at play (28).     
Among Canadian patients with diabetes, marital status impacted the likelihood of experiencing a 
diabetes-related complication in diverse ways. Separated patients were more likely to report having a 
macro-vascular complication than their married counterparts. Separated patients were also more likely 
to have neuropathy and kidney failure compared to their married counterparts. Similarly, the literature 
suggests that those patients without partners are at an increased risk for developing neuropathy 
(OR=2.00, CI: 1.00-1.87) and visual impairments (OR=1.42, CI: 0.99-2.03) as a result of their diabetes 
compared to married patients (9) (15). It appears that being married is protective against diabetes-
related complications, as it has been found to lower one’s risk of premature death as a result of diabetes 
by 50 to 64 percent (17). Being married may provide diabetic patients with an immediate social support, 
and this may facilitate better adherence to prescribed treatment plans and self-care regimens (29). 
Others have proposed that not only being married but having a high level of marital satisfaction may be 
associated with a lower risk of developing metabolic syndromes (30). Further examination of the ways 
marital status and the real and perceived satisfaction it brings interacts with diabetes-related 
complication may be required to better understand this association. 
The link between socioeconomic status and diabetes-related complications has warranted much 
attention, and the literature suggests that a low level of education and a low income can contribute 
negatively to an individual’s lifestyle, which in turn has been shown to elevate their risk of developing 
diabetes and its related complications (28)(31). Further, higher levels of education have also been 
shown to reduce the likelihood that a diabetic patient will develop micro-vascular complications, end-
stage renal disease, coronary artery disease, and retinopathy (18) (19).  In the present study, this trend 
was also observed: that is, more highly educated patients had a lower likelihood of developing certain 
diabetes-related complications including: heart disease and high blood pressure. When considering 
income, a similar association was also found: patients with an annual income of more than $50,000 
were less likely to report both micro-vascular and macro-vascular complications compared to those who 
earned less than $50,000 annually. This may be explained, in part, by the fact that high levels of 
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education and income are known to be associated with better adherence to prescribed medication 
regimens and an increased awareness of preventive health care programming (32)(33)(34). In sum, high 
levels of education and income are protective against diabetes-related complications suggesting the 
need to target health policies and programming at diabetes patients with lower levels of education and 
income.   
Diabetes Status  
Findings from the present study suggest that a patient’s type of diabetes has little bearing on the 
diabetes-related complications they experience. With the exception of high blood pressure, no other 
significant associations were detected between diabetes-related complications and a patient’s type of 
diabetes. In contrast, the literature commonly suggests that, in comparison to patients with type I 
diabetes, patients with type II diabetes are at an increased risk of neuropathy and macro-vascular 
complications as a result of their diabetes (20)(35). This trend may not be observed in the present study 
as a result of the difference in the number of patients reporting each type of diabetes: According to the 
SLCDC-DM-2011, 8.22 percent of patients reported having type I diabetes and 79.75 percent of patients 
reported having type II diabetes.   
Unlike a patient’s type of diabetes, the length of time that a patient has diabetes was strongly 
associated with both micro-vascular and macro-vascular complications in this study. This is unsurprising 
given that the duration of diabetes is a well-established predictive factor of diabetes-related 
complications in the literature (9)(15)(17). In fact, each 10-year increase in duration of diabetes has 
been shown to elevate patients’ risk of experiencing diabetes-related complications, including coronary 
heart disease (OR=1.4), macro-vascular complications (OR=1.13), micro-vascular complications 
(OR=1.28), and premature death (1.15) (21) (36).  
In both the present study and in the literature, injection of insulin has been shown to be strongly 
associated with micro-vascular complications (15)(22). However, the literature offers a more 
comprehensive picture, and suggests that only those patients with type II diabetes are put at risk when 





Risk Factors  
Analysis of risk factors reveals that high level of A1C, inappropriate BMI, and low physical activity are all 
positively associated with diabetes-related complications to varying degrees. Our findings suggest that 
high levels of A1C was the most important risk factor in predicting diabetes-related complications, and 
this predictive value has also been noted in the literature (25). In contrast, the risk of developing 
diabetes-related complications as a result of cigarette smoking appears to be more nuanced. In the 
present study, daily cigarette smoking was significantly associated with two individual diabetes-related 
complications: erectile dysfunction and retinopathy. There was no evidence to support an association 
between cigarette smoking and both micro-vascular and macro-vascular complications. This differs from 
the literature, where cigarette smoking has been shown to exacerbate serious diabetes-related 
complications, including cardiovascular disease, kidney disease and neuropathy (23). The lack of 
relationship in the present study may reflect the cross-sectional design of the SLCDC-DM-2011.   
Another risk factor that was identified as a strong predictor of diabetes-related complications in this 
study was an inappropriate BMI score, and specifically being overweight or obese. More specifically, 
being overweight or obese was more predictive of: diabetes-related complications for type II diabetes 
patients; having erectile dysfunction; and, having high blood pressure. These findings complement the 
literature in which BMI has been shown to be associated with chronic diabetes-related complications, 
including an increased risk of cardiovascular complications (HR=1.34 to HR=2.45), cerebrovascular 
complications (HR=1.30 to HR=2.00), renal complications (HR=1.31 to HR=2.23), and lower extremity 
complications (HR=1.41 to HR=2.95) (19)(38)(39)(40). Being overweight or obese is oftentimes linked to 
physical inactivity, and the present study finds that being physically inactive is another risk factor for the 
development of diabetes-related complications, including micro-vascular complications, such as foot 
ulcers or poor circulation, as well as stroke and heart disease. Previous studies have implicated physical 
inactivity as a risk factor for the development of diabetes-related complications, including impaired 
renal function, retinopathy, cardiovascular disease, and hypertension (24)(41). Importantly, because 
physical inactivity has not only been linked to the development of diabetes-related complications among 
diabetes patients, but also the development of diabetes itself (42), there is a need to further the 




Self-Monitoring Behaviour  
Our findings reveal that frequent self-monitoring behaviour was protective against some diabetes-
related complications, including stroke. Similarly, the literature suggests that the total rate of all 
diabetes-related complications was lower among patients who self-monitor their blood glucose 
compared to those who do not (43). In order to gain this protective effect, patients may not be required 
to self-monitor daily: that is, self-monitoring less frequently than daily was still associated with a lower 
likelihood of reporting retinopathy, cataracts, and kidney failure in the present study. However, 
although there are a number of proven benefits of self-monitoring behaviour, this behaviour has not 
consistently been found to be independently associated with improved survival among diabetes patients 
(17). This inconsistency was also observed in the present study where differing frequencies of self-
monitoring behaviour were protective against some diabetes-related complications, but not others. One 
caveat in the present study is that the temporal relationship between engaging in self-monitoring 
behaviour and subsequent experience of diabetes-related complications was not encountered for. 
Alternatively, associations observed in the present study may be due to incomplete adjustment of 
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CHAPTER 3-EFFECTS OF PHARMACY-BASED INTERVENTIONS ON THE CONTROL AND 
MANAGEMENT OF DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS 
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In this chapter, I aim to assess the current state of evidence on the effectiveness of pharmacy-based 
interventions in control and management of diabetes. Based on the findings in chapter 2, high levels of 
A1C and inappropriate levels of BMI are considered main risk factors associated with most of diabetes-
related complication in Canada. In this chapter I conduct a systematic review and meta-analysis to 
assess the effect of pharmacy-based interventions on reducing the main risk factors identified in chapter 
2. The findings from this chapter are used as main input parameters for building the micro-simulation 
















Promotion of community-based interventions, including early screening programs and education about 
how to effectively self-manage diabetes, can lead to a decrease in the burden of diabetes and related 
complications (1). Pharmacy-based interventions include a wide range of services, which aim to enable 
patients with diabetes to have greater control and management of their disease, such as pharmacist 
consultations, patient education about self-monitoring and self-management, preventive programming 
about lifestyle modifications, reminders about annual physical examinations, medication therapy 
adherence assistance, providing information about the correct use of insulin, antihyperglycemic 
medications,  and other interventions to increase awareness about diabetes management. Recent 
reviews of the effectiveness of pharmacy interventions have demonstrated their positive impact on 
clinical outcomes. These positive impacts likely reduce the burden of diabetes-related complications, 
and, by doing so, subsequently lead to reductions in diabetes-related morbidity and mortality 
(2)(3)(4)(5) . 
Although systematic reviews have evaluated the clinical and non-clinical effectiveness of pharmacy-
based interventions among diabetes patients (2) (3) (4), no recent work has calculated the pooled effect 
of pharmacy-based interventions on mean reduction of A1C, except one meta-analysis that conducted in 
2007(6). Therefore, previous reviews noted that there is a need to conduct a future and updated meta-
analysis (3). The aim of this systematic review and meta-analysis was to evaluate the effects of 
pharmacy-based interventions on clinical outcomes associated with diabetes-related complications as 
well as non-clinical outcomes among people with diabetes.  We followed PRISMA guidelines in 
conducting this systematic review and meta-analysis. The PICOs (Population, Intervention, comparison, 
outcome and study design) for this study were defined to focus the research question following PRISMA 
guidelines: we considered all patients with Diabetes (Level of HbA1c > 6.5%) as population; pharmacy-
based interventions as an intervention; mean change of A1C level, BMI, health care utilization and 
quality of life as outcomes, usual care as a comparison and randomized control trial (RCTs) and non-
randomized studies with comparator group as study designs. We performed the meta-analysis to assess 
the pooled effect of pharmacy-interventions on the mean reduction of A1C and BMI (kg/m2). 
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3.2.Material and methods 
3.2.1.Search strategy 
In February 2017, a search strategy was used to retrieve all relevant studies from the following 
databases: MEDLINE, EMBASE, CINAHL, and Cochrane Central Registered for Controlled Trials. The 
search strategy was developed with the assistance of a medical information specialist in MEDLINE via 
OVID. Keywords used in the search strategy were identified through experts’ opinion and controlled 
vocabularies (Medical Subject Headings = MeSH and Excerpta Medica Tree = EMTREE). The keyword 
diabetes mellitus was used to identify literature discussing the health issue at hand. The keywords 
pharmacy, pharmacies, pharmacy service, community pharmacy service, pharmaceutical care, 
pharmaceutical service, and pharmacist were used in combination with diabetes mellitus to identify 
literature discussing the intervention at hand. This search strategy was adapted for EMBASE, CINAHL, 
and Cochrane databases. To ensure a highly sensitive search strategy, filters were not used to limit the 
retrieval of studies to those with a randomized controlled trial study design, those written in a particular 
language, or those from a certain time period. However, restrictions were placed on the study 
population in the initial retrieval of papers, and study populations had to include human participations 
and adults over the age of 18. Citation tracking of related papers was applied, and the references of all 
included studies were manually checked. Details of the search strategy are shown in appendix C. 
3.2.2. Study selection 
Two reviewers (MY-MF) independently screened all titles and abstracts retrieved during the initial 
search. Titles and abstracts were screened based on inclusion criteria, which included relevance to the 
research question. The full text was obtained for each study that met these criteria and screened against 
the inclusion criteria outlined below. Any disagreement concerning the eligibility of a study for this 
review was resolved through discussion with the third reviewer (HV). Duplicate publications of the same 
study were excluded unless subsequent publications provided additional information about an outcome 
of interest. The study selection process is presented in a Preferred Reporting Items for Systematic 
Review and Meta-Analysis (PRISMA) flow chart in (Figure 3.1) (7). 
3.2.3. Inclusion and exclusion criteria 
In this review we focused on AIC because this biomarker is considered a progressive risk factor for 
microvascular and macrovascular complications, hospitalization and death in patients with diabetes (8). 
We also focused on BMI (kg/m2) because obesity is considered one of the most important risk factors 
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for developing diabetes and its complications (9). We included mean difference of A1C and BMI across 
intervention and control group derived from randomized controlled trials in meta-analysis in order to 
ensure a high validity of reported findings. Additionally, non-clinical outcomes were considered in the 
systematic review but not in the meta-analysis.  Since utilization of healthcare services is an important 
determinant of health outcomes (10) and quality of life is a significant measure of the value of health 
outcomes, we focused on health care utilization (inpatient admissions and emergency visits), and  also 
quality of life in this review as non-clinical outcomes. Measures of these outcomes were derived from 
randomized controlled trials, non-randomized controlled trials, or retrospective studies with a 
comparator group. The inclusion of non-clinical outcomes creates a more comprehensive understanding 
of the effects of pharmacy-based interventions.  
Studies were included in the systematic review if they met the following criteria: 1) the exposure of 
interest was a pharmacy-intervention which includes education about diabetes, self-management, self-
monitoring of the condition, modification of pharmacotherapy, and/or patient counselling; 2) studies 
which reported at least one of the outcomes of interest including; the mean change in A1C level, BMI 
(kg/m2), health care utilization, and/or quality of life between intervention and control group; and, 3) it 
was a randomized controlled trial, non-randomized controlled trial, or retrospective study with a 
comparator group. In contrast, the meta-analysis included only those studies in which a randomized 
controlled trial study design was used. Studies were excluded if they met the following criteria: 1) 
selected outcomes were not reported; 2) other educational interventions outside of the pharmacists’ 
scope of practice; and, 3) studies in which there was no control group. 
3.2.4.Quality assessment 
Quality assessment has been done by two reviewers independently. All of the included studies were 
assessed according to the Cochrane risk of bias tool, which includes consideration for the following 
criteria: 1) random sequence generation; 2) allocation concealment; 3) blinding of outcome assessment; 
4) incomplete outcome data; 5) selective reporting; and 6) other sources of bias. Our application of this 
tool did not include blinding of study participants and personnel because this was inconsistent with the 
design of pharmacy- interventions. We checked all criteria for a judgment of “low risk “,”high risk” and 
“unclear” as explained in detail in the Cochrane systematic review handbook and each study was rated 
as either “low risk”, “high risk“ or “unclear”. 
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3.2.5. Data extraction 
Data extraction has been done by two reviewers. Data were extracted and entered into a data 
extraction sheet, which included descriptive information about the study sample, the intervention and 
the results. The following data points were extracted from each study: last name of first author, year of 
publication, type of study design, target population, number of participants in the intervention group, 
number of participants in the control group, duration of follow-up period, outcome measures, and 
results. A summary of data extraction sheet is shown in Table 3.1. 
3.2.6. Data synthesis and analysis 
To calculate the mean difference of A1C levels and/or BMI between intervention and control groups, we 
subtracted the baseline (b) level or score from the follow-up (fu) level or score to find the change over 
time. Next, we subtracted the change in the control group from the corresponding change in the 
intervention group to quantify the net effect. The standard error (SE) was reported for each net effect 
calculated from the included studies. The SE reported was calculated either based on the confidence 
interval or p-value of the net effect, or based on the standard deviation (SD) of effects within parallel 
groups(20)(see Table 3.2 ). Meta-analysis was performed using Stata (version 14). The heterogeneity of 
studies in the meta-analysis was assessed using the Q test and we used I2 statistic to quantify 
heterogeneity. Additionally, potential publication bias among studies in the meta-analysis was assessed 
using the Egger’s test and Begg’s adjusted rank correlation test. Regarding sensitivity analysis, we used 
Influence Analysis based on Stata’s matainf command to examine the effect of excluding each study on 
the pooled estimate of standardized mean difference (SMD) and explore the heterogeneity among 

















Table 3.1. Summary of 44 studies assessing pharmacy-based intervention for patient with type 2 diabetes 
 
No First Author 
(Year) 
Type of Study Participants Intervention Follow-
up 
Main Outcome(s) Result 














glucose, and quality 
of life 
There was a decrease in the mean 
capillary blood glucose and improvement 
in the mean quality of life scores reported 
for the intervention group (P <0.05). 














quality of life 
(HRQOL) 
The overall HRQOL was significantly 
improved at 12 months in the 
pharmaceutical care intervention group 
when compared to the control group (P 
<0.0001). 









A1C, BMI, Blood 
pressure, Blood 
Significant reductions were noted in A1C 
and all secondary outcomes improved 
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profile, and Quality 
of life 
among members of the intervention 
group (P =0.001). 














A1C, BMI, Blood 
pressure, CHD risk 
factors, and Quality 
of life 
There were significant reductions in A1C 
and blood pressure, and improvements in 
quality of life scores among members of 
the intervention group. Theres were no 
significant changes in the control group. 

















A1C was significantly reduced for the 
intervention group. All secondary 
outcomes, including quality of life, 
improved among members of the 
intervention group.  







care plan and 
12-
months 
A1C, Fasting blood 
glucose, and 
There were significant reductions in A1C 
and  blood glucose among members of 
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controlled trial 121 control diabetes education   Medication 
adherence scale 
the intervention group. A higher 
proportion of members in the 
intervention group reported medication 
adherence.  
       
 













A1C, BMI ,CHD risk 
factors, LDL, HDL, 
and dherence to 
medication regimen 
A1C was significantly reduced in the 
intervention group (P < 0.001). 
Additionally, members of the 
intervention group had a statistically 
significant reduction in CHD risk (P = 
0.013).  















medical expenses  
A1C significantly decreased for the 
intervention group (P ≤ 0.001). Medical 
expenses and hospitalizations did not 
significantly differ across groups (P = 
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consultation 0.767).  













A1C, BMI, lood 
pressure, and CHD 
risk factors  
Reductions were greater among 
members of the intervention group 
compared to the control group for A1C 
and blood pressure (P < or = 0.043). The 
risk of the first CHD event decreased 
among members of the intervention 
group (P = 0.002).  














A1C, CHD risk 
factors, lood 
pressure, LDL, and 
foot care  
 
Significant improvements from baseline 
were found in the intervention group for 
exercise, foot care, and attainment of 
goal levels of A1C, LDL-C, and blood 
pressure.  










A1C, LDL, foot 
screening, and 
There was a greater reduction in A1C 
among members of the intervention 
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29 control and provision of 
diabetes education 
by a clinical 
pharmacist 
retinal examination group (P = 0.03). LDL measurements, 
retinal examinations, and monofilament 
foot screening were more frequent in the 













A1C, and fasting 
blood glucose 
The mean fasting blood glucose and A1C 
of members of the intervention group 
decreased significantly (P < 0.001). 

















A1C, BMI, fasting 




and drug knowledge 
There were significant differences in the 
intervention group in: A1C, drug-related 
problems, and drug knowledge (P < 
0.0001); fasting blood glucose (P = 
0.0004); total cholesterol (P = 0.0054); 
and systolic blood pressure (P = 0.0006).  
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and counseling  
4-
months 
A1C, fasting plasma 
glucose, blood 
pressure LDL, HDL, 
and quality of life 
There were statistically significant 
differences in A1C (P = 0.003) and fasting 
plasma glucose (P = 0.022). no significant 
changes in blood pressure, lipid profile, 
renal function, weight, and quality of life. 



















There were significant reductions in A1C 
in the intervention group (P = 0.019). The 
intervention group had statistically 
significant improvements in other 
outcome measures. 














There were significant decreases in A1C 




















A1c, blood pressure, 




There were significant improvements for 
A1C , LDL and blood pressure in the 
intervention group (P < 0.05). 
Additionally, more intervention patients 
were screened for retinopathy and 













Quality of life, health 
care utilization, 
blood pressure, 
blood glucose levels, 
and Diabetes 
knowledge 
A significant difference was not found for 
quality of life or health care utilization. 
Blood pressure improved in the EI group 
(P = 0.020) and the EI group increased 
their disease-related knowledge (P = 











Patient counseling  
12-
months 
A1C, BMI, blood 





There was a significant reduction in A1C 
(P = 0.0008) and cholesterol (P < 0.001) 
for the intervention group. The difference 
was not significant for BMI, blood 
pressure, health care utilization and DES 













management   
6-
months 
A1C, blood glucose, 
BMI, blood pressure, 
cholesterol, 
triglycerides, and 
Quality of life  
There was a significant reduction in A1C 
and mean blood glucose in the 
intervention group (P < 0.01). 
Improvements were also seen in blood 
pressure and quality of life among 
members of the intervention group.  











A1C, BMI, Fasting 
blood glucose, blood 
pressure,  
There were significant reductions in A1C 
(P = 0.011) and fasting blood glucose (P = 
0.002). Total cholesterol and LDL-C were 
64 
 
37 control LDL, HDL, and 
triglycerides  
also significantly reduced in the 
intervention group (P = 0.001).  













promotion of a 
healthy lifestyle  
6-
months 
A1C, fasting plasma 
glucose, adherence 
to medication, and 
knowledge score 
There was a significantly reduction in A1C 
among members of the intervention 
group (P = 0.009), as well as improved 
self-management and better knowledge 
of diabetes. 
23 Mansell , K 
(2016)(34) 
Cluster 
randomized study  
21 
Intervention 
9 Control  






Mean A1C change was -1.96 and -0.70 in 
the intervention and control group 
respectively ( p= 0.37) 










A1C, BMI, fasting 
blood glucose, 
 significant reduction in A1C showed in 
intervention group (P = 0.001), as well as 
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reductions in fasting plasma glucose, 
total cholesterol, LDL-C, triglycerides and 















A1C, BMI, systolic 
blood pressure, 
diastolic blood 
pressure, LDL, HDL, 
triglycerides, CHD 
risk factors 
There were significant reductions in A1C  
(P < 0.00), and all other clinical outcomes 
such as CHD risk factors (P < 0.001). 














A1C, blood pressure, 
fasting lipids, and 
quality of life 
Compared to baseline, A1C was 
significantly greater in the intervention 
group (P = 0.0075). The difference in the 
number of severe hypoglycemia events 
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education   between the two groups was not 
significant (P = 0.1276). Well-being score 
improved significantly in the intervention 




















medication regimen  
A1C did not differ between groups (P = 
0.61). The appropriateness of medication 
did not improve (P = 0.65), and self-
















A1C, systolic blood 
pressure, diastolic 
blood pressure, and 
LDL 
A1C and systolic blood pressure were 
significantly reduced in the intervention 
group (P < 0.02). no significant change in 





















Quality of life, 
medication 
adherence, blood 
glucose level, and 
Diabetes knowledge 
There was a significant increase in quality 
of life, diabetes knowledge scores, and 
adherence scores (P < 0.05) among 
members of the intervention group.  






















care, health service 
The intervention group showed 
significantly greater improvements than 
the control group for systolic blood 
pressure (P = 0.007), diastolic blood 
pressure (P = 0.008),  and A1C (P = 0.02). 
Intervention patients had greater 
improvements in both diabetes 
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utilizations knowledge and satisfaction. Changes in 
total cholesterol levels and health service 
utilization were not significant.  















At 24 months after baseline, A1C was 
significantly decreased (P = 0.04).  















A1C, BMI, quality of 
life, diastolic blood 
pressure, systolic 
blood pressure, LDL 
and HDL 
There was a significant reduction in A1C 
(P = 0.003), systolic blood pressure (P = 
0.02), and LDL (P = 0.01) in the 
intervention group. Quality of life was 
significantly higher in the intervention 
group (P = 0.002). 
33 Sriram S Randomized 60 Pharmaceutical 8- A1C, BMI, quality of 
A1C and fasting blood glucose were 
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months life, fasting blood 
glucose, and 
satisfaction score 
significantly reduced (P < 0.01). an 
improvement in the quality of life score  
showed in intervention group(P < 0.01).   













A1C, and fasting 
blood glucose 
Mean A1C and fasting blood glucose 
decreased among members of the 
intervention group compared to the 
control group (P < 0.013).  
















A1C, systolic blood 
pressure, LDL, HDL, 
lipid profile, and 
tobacco use  
There was a significant reduction in A1C, 
systolic blood pressure, triglycerides, LDL, 
and HDL  in the intervention group (P < 
0.05). There was no significant change in 
lipid control or tobacco use between the 
groups. 










A1C, BMI, fasting 
blood sugar, LDL, 
There was a significant reduction in A1C 
and fasting blood sugar (P < 0.05) among 
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adherence, and  
self-care activity  
members of the intervention group. 
Knowledge, medication adherence, and 
self-care activities increased significantly 
for the intervention group compared to 
the control group (P < 0.05). 
















and rate of 
emergency visits  
There was significant total cost savings 
(pharmacy + medical) compared with the 
corresponding control groups (P = 0.003). 















rate of emergency 
visits 
The intervention group experienced 
significant reductions in A1C and a 
decreased rate of hospitalization. 
Compared to the control group, the 
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intervention group also had a lower rate 
of emergency visits.  


























There was a greater reduction in A1C (P < 
0.001) and greater reduction in fasting 
capillary glycemia reduction (P = 0.022) in 
the intervention group. However, there 
were no significant differences in any 
other clinical measures between the 
groups. The MRCI decreased at the end of 
the follow-up period. 














A1c, BMI, blood 
pressure, and LDL 
A1C was reduced significantly among 
intervention patients relative to the 
control group (P < 0.001). Similarly, there 
were significant improvements reported 
for blood pressure and LDL among 
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management  intervention patients. No significant 
















A1C, health service 
cost, and health 
service utilization 
The level of A1C was significantly reduced 
in the intervention group. The 
intervention group experienced a smaller 
average increase in health service costs. 
42 Skinner JS 
(2015)(53) 
Retrospective 













A1C, systolic blood 
pressure, diastolic 
blood pressure, LDL, 
HDL, and 
triglycerides  
A1C was lower in the intervention group 
compared to the control (P < 0.001). 
Similarly, LDL was lower in the 
intervention group compared to the 
























There was a greater, statistically 
significant reduction in A1C in the 
intervention group (P = 0.001). there was 
less likely to have an ED visit in 
intervention group (P = 0.040), but no 
significant difference in the hospital 
admission rates was shown. 


















A1C, blood pressure, 
cost of Diabetes, and 
lipid Profile 
There was a significant reduction in A1C, 
blood pressure, and lipid levels in the 
intervention group. The cost of diabetes 




3.3.1. Study selection 
The initial search identified 951 studies, of which 361 were duplicates and thus excluded. During this 
screening, 479 studies were excluded because they were irrelevant to our research question. The 
remaining 111 studies underwent full-text assessment using the inclusion and exclusion criteria 
provided above. During this stage, a total of 68 studies were excluded: 24 studies were excluded 
because they were not compatible with this review’s outcomes of interest; 22 studies were excluded 
because the interventions were not pharmacy-based; 11 studies were excluded because they did not 
follow a proper study design; and, 10 studies were excluded because they did not focus on diabetes. 
Thus, a total of 44 studies were included in the qualitative review. The process of selection of these 
studies is depicted in a PRISMA flow diagram (Figure 3.1) and a detailed description of the included 
studies is provided in Table 3.1. Of all included studies, 40 studies focused on pharmacy-based 
educational and behavioural consultation interventions addressing self-management, self-monitoring, 
medication adherence, and lifestyle modification and only 4 studies (38)(29)(50)(48) focused on 
medication-related interventions such as pharmacotherapy and follow-up programs . Of the 44 studies: 
39 studies reported a mean reduction of A1C (%) as a clinical outcome; 16 studies reported a difference 
of BMI; 12 studies reported the effects of a pharmacy intervention on quality of life; and 9 studies 
reported the effects of a pharmacy intervention on health care utilization. Of the 44 studies, 42 studies 
examined people with type 2 diabetes and 2 studies (37) (49) considered people with type 1 diabetes as 
a target population. The Cochrane risk of bias tool was used to assess the risk of bias using six criteria.  
To assess random sequence generation, considerations were made for the type of study design. 36 
studies made use of randomized controlled trials, two studies made use of non-randomized controlled 
trials, and six studies used a retrospective non-randomized design including three cohort studies, 1 case-
control, one longitudinal and one quasi-experimental study. Studies that did not use a randomized 
controlled design were excluded from the meta-analysis. Among studies based on randomized 
controlled trials, consideration of allocation concealment and blinding of outcome assessment were 
difficult to assess because of the lack of information provided in most studies. Similarly, most studies 
also lacked adequate information about incomplete outcome data and selective reporting (Figure 3.2). 
Therefore, 32 studies were deemed of appropriate quality and were included in the meta-analysis 
calculating the pooled standardized mean difference (SMD) of A1C (%) and 13 studies were deemed of 
appropriate quality and were included in the meta-analysis calculating the pooled standardized mean 




Table 3.2. mean difference of A1C and BMI from baseline to follow-up and net effect in intervention 













Jaber LA 2.3 0.71 0.1 0.71 2.2 0.484 0.01 
Sarkadi A 0.04 1.07 0.3 1.05 -0.26 0.251 0.01 
Odegard PS 2 1.07 1.8 1.05 0.2 0.230 0.11 
Rothman Rl 2.5 1.07 1.6 1.05 0.9 0.150 0.05 
Suppapitiporn S 0.25 1.07 -0.79 1.05 1.04 0.112 0.05 
Clifford RM 0.5 0.63 0 0.45 0.5 0.157 0.002 
Cohen HM 2.1 1.95 0.9 2.92 1.2 0.253 0.03 
Fornos JA 0.5 2.40 -0.7 2.69 1.2 0.192 0.08 
Scott DM 1.72 1.07 0.7 1.05 1.02 0.185 0.003 
Krass I 1 0.71 0.3 0.63 0.7 0.140 0.01 
Al Mazroui NR 1.6 0.56 0.1 0.56 1.5 0.180 0.01 




Cohen LB 0.41 0.71 0.2 0.71 0.21 0.202 0.05 
Farsaei S 1.8 2.25 -0.1 1.42 1.9 0.161 0.3 
Sriram S 1.71 0.30 0.72 0.22 0.99 0.306 0.05 
Mehuys E 0.6 1.55 0.1 1.30 0.5 0.123 0.1 
Neto PR 0.7 0.61 0 0.73 0.7 0.153 0.8 
Jacobs M 1.8 1.84 0.8 2.26 1 0.160 0.003 
Chan CW 1.57 0.71 0.4 0.71 1.17 0.227 0.01 
Kraemer DF 0.52 1.09 0.16 1.03 0.36 0.251 0.008 
Planas LG 0.52 1.34 -0.11 1.23 0.63 0.285 0.02 
Jarab AS 0.8 1.30 -0.1 1.05 0.9 0.166 0.01 
Ali M 1.6 0.83 0.6 0.90 1 0.320 0.001 
Mourão AO 0.6 1.04 -0.7 1.05 1.3 0.219 0.001 
Chung WW 1.4 0.71 0.2 0.71 1.2 0.151 0.16 
Obarcanin E 0.9 0.38 0.08 0.29 0.82 0.329 0.001 
Cani CG 0.57 1.99 0.08 2.26 0.49 0.240 0.001 
Wishah RA 1.7 1.07 0.3 1.05 1.4 0.215 0.05 





Lim PC 0.9 0.39 0.08 0.22 0.82 0.312 0.001 
Jameson JP 1.5 2.65 0.4 1.60 1.1 0.200 0.06 
Chen JH 0.83 1.84 -0.43 2.12 1.26 0.205 0.002 
BMI Level 
Clifford RM 0.6 0.84 -0.1 0.45 0.7 0.159 0.005 
Fornos JA 0.9 0.84 0.3 7.42 0.6 0.189 0.01 
Scott DM 0.4 4.98 0.2 6.11 0.2 0.175 0.1 
Krass I 0.3 0.89 0.2 1.14 0.1 0.122 0.3 
Al Mazroui NR 1.05 1.74 -0.01 2.02 1.06 0.133 0.004 
Netro PR 0.1 0.30 0 0.10 0.1 0.145 0.001 
Sriram S 1.85 0.21 -0.09 0.29 1.94 0.531 0.01 
Ali M 3.86 5.87 1.09 7.97 2.77 0.298 0.05 
Jarab AS 0.5 1.97 -0.4 1.61 0.9 0.163 0.1 
Mourão AO -0.1 0.45 0.3 0.63 -0.4 0.207 0.1 
Wishah RA 0.5 4.95 -0.5 6.18 1 0.195 0.11 




3.3.2. A1C (%) outcome 
Among 32 randomized controlled trials, 4,132 participants with type 2 diabetes mellitus, including 2,100 
in an intervention group and 2,032 in a control group, were examined with an average of 9.96 months 
follow-up duration (3-36 months). Participants in the interventions group were exposed to some type of 
pharmacy-based intervention. A random effect model was used to estimate the pooled standardized 
mean difference in A1C (%) between the intervention and the control group. Results from the chi-square 
test for heterogeneity were significant (P < 0.001) and I-squared (93.1%) showed high heterogeneity 
between studies, therefore random effect models were used. The pooled estimate of the standardized 
net mean difference of HA1C (%) across groups was 0.96% (95% CI 0.71 to 1.22; P<0.001). The forest 
plot shows the standardized mean difference of A1C (%), and 95% CI for each study included in the 
meta-analysis (Figure 3.5). Importantly, there was no evidence of publication bias indicated by the 
Egger’s test (P = 0.20) and Begg’s adjusted rank correlation test (P=0.52)  .Results of metan-based 
Influence Analysis to examine the effect of excluding each study on the pooled estimate of SMD 
determined that 8 studies including; Sriram S et al (44) Al Mazroui NR et al (15) Sarkadi A et al (42) Jaber 
LA et al(25) Lim PC et al(32) Obarcanin E et al(37) Chung WW et al(17)and  Wishah RA et al (47)had the 
greatest impact on the pooled effect respectively; after excluding these 8 studies the pooled SMD was 
0.65%(0.49% to 0.80%) and Heterogeneity decreased to I2=74.3%    
3.3.3. BMI (kg/m2) outcome  
Among studies under this review, 13 randomized controlled trials qualified for inclusion in the meta-
analysis calculating the pooled mean difference in BMI. In total, 1,827 participants with type 2 diabetes 
mellitus, including 863 in an intervention group and 859 in a control group, were examined with average 
10.66-month follow-up duration (4-36 month). Participants in the intervention group were exposed to 
some type of pharmacy-based intervention. A random effect model was used to estimate the pooled 
standardized mean difference in BMI between the intervention and the control group. Results from the 
chi-square test for heterogeneity were significant (P < 0.001) and I-squared (94.5%) showed high 
heterogeneity between studies, so random effect model was adopted. The pooled estimate of the 
standardized net mean difference in BMI across groups was 0.61(95% CI 0.20 to 1.03; P=0.000). The 
forest plot shows the standardized mean difference of BMI and 95% CI for each study included in the 
meta-analysis (Figure 3.6). Importantly, there was no evidence of publication bias indicated by the 
Egger’s test (P = 0.08) and Begg’s adjusted rank correlation test (P=0.83).  Results of metan-based 




indicated that ,Sriram S et al(44) had the greatest impact on pooled effect; after excluding this study, the 
pooled SMD was 0.20(0.07 to 0.34) and Heterogeneity decreased to I2=48.8%.    
Figure 3.2. Risk of bias assessment in included studies 
 




















Figure 3.5. Forest plot of standardized net mean difference of A1C (baseline to the last follow-up) in 









Figure 3.6. Forest plot of standardized net mean difference of BMI (kg/m2) (baseline to the last 
follow-up) in intervention versus control group in 13 randomized controlled trials 
 
 
3.3.4. Quality of life outcome 
Nine randomized controlled trials reported quality of life scores as one of the outcomes of a pharmacy-
based intervention for patients with diabetes. In total, there were 1,564 participants, including 809 in an 
intervention group and 705 in a control group with average of 9.22 months follow-up duration (6-12 
months). However, a meta-analysis was not conducted due to the variability of instruments used to 
assess the quality of life across included studies. Six included studies in this review demonstrated that 
pharmacy-based interventions are directly associated with improvements in quality of life among 
patients with diabetes in the intervention group compared to control group. (13)(14) (16) (31)(40) 




specific questionnaires, just two studies reported significant improvement in the intervention versus 
control group after the follow-up duration (16)(44). Cani CG et al (16) used a validated Brazilian version 
of a diabetes quality of life measure and reported a net difference of 8.95 in the quality of life score 
improvement across the intervention and control group (P = 0.001). Sriram S et al(44) used the Audit of 
Diabetes-Dependent Quality of Life (ADDQOL) tool to assess the quality of life in their respective 
samples and reported that the net difference of quality of life score was 1.09 in the intervention 
compared to the control group (P = 0.01). Among six studies assessed the quality of life using generic 
questionnaires, four studies demonstrated a significant improvement in the intervention group versus 
control group (13) (14)(31)(40) . Adibe et al (13) reported that the net difference of overall HRQOL score 
was 0.22 between intervention and control groups (P = <0.0001). The study conducted by Ali et al(14) 
used the short form SF-36 to compare the quality of life scores between patients in the intervention and 
patients in the control group. This study reported a net difference of 16.99 in the quality of life score 
improvement across the intervention and control group (P = 0.001). Krass et al (31) used EQ-5D (health 
state scale score) and reported a net difference of 4.2 in quality of life between the intervention and 
control groups (P = 0.02). Lastly, Ramanath KV et al (40) used the World Health Organization-Brief 
Quality of Life questionnaire, and results showed a positive effect of pharmacy-based interventions on 
quality of life among diabetic patients. Specifically, the net difference in the quality of life score was 7.39 
for the intervention group compared to the control group (P = 0.01). Figure 3.7 shows the net mean 
difference of improvement in quality of life in intervention versus control group for each study included 
in this review. 
3.3.5. Health service utilization outcome 
In total, six studies (three RTCs and three non-RTCs) estimated differences in heath service utilization 
related to diabetes, associated with patients receiving pharmacy-based intervention and those not 
receiving the pharmacy-based intervention; all of the studies considered a 12 month follow-up duration 
to assess the effect of intervention.  
The three randomized controlled trials studies noted no significant differences in health care service 
utilization outcomes across intervention and control groups. Kjeldsen LJ et al noted no significant 
differences across groups in terms of the number of medications, general physician visits, and 
hospitalization rates (29). Additionally, differences in medication and supplies usage based on insurance 
claim data was not significantly different between those receiving pharmacy counseling and those not 




in health care utilization rate between patients receiving pharmacist care and those not receiving such 
care.  
Among non-RTCs studies, two studies (48) (49) noted a significant reduction in inpatient admissions and 
one study (54) showed a significant reduction in emergency visits in intervention group compared with 
the control group. Brophy et al (48) conducted a retrospective quasi-experimental study to assess health 
care service utilization among patients receiving collaborative pharmacy benefit manager health plans. 
They reported lower hospitalization rates in the intervention group compared with control group 
(P=0.002). A retrospective cohort study was performed by Chung N et al (49) to estimate the difference 
in the hospitalization rate of patients referred to a clinical pharmacist versus patients in a control group. 
They reported an average of eight more hospitalizations for patients in the control group (P = 0.06). A 
retrospective cohort study demonstrated that diabetic patients in the intervention group were less likely 
to visit the emergency room (1.67% vs. 4.21%, P = 0.04), but there was no difference in inpatient 
admission rate compared to controls (54). Figure 3.8 shows the net difference in reduction of inpatient 















Figure 3.7. Net difference in improvement of quality of life score across intervention and control 
group among nine randomized controlled trials  
 
Figure 3.8.Net difference in reduction of inpatient admission and emergency visit across intervention 







This systematic review examined the effectiveness of pharmacy-based interventions among patients 
with diabetes. Although pharmacy-based interventions in this review included a wide range of 
interventions which have been implemented in different health care settings, there is some consistency 
regarding type of interventions among studies.  Forty studies considered education-oriented programs 
for patients with type 2 diabetes; these educational programs covered areas such as self-management, 
self-monitoring, medication adherence, lifestyle modification and increased awareness about diabetes-
complications. Only four studies have not included education –oriented interventions and focused on 
pharmacotherapy interventions to decrease risk of medication related problems. Three of these four 
studies were excluded from the meta-analysis because of study design (48) (50) and not reporting of 
A1C (29) and hence only one study of these four (38) was included in meta-analysis. Hence, although 
there is some inherent heterogeneity, the consistency of these studies lends some assurance to the 
results observed.     
Our finding about the pooled standardized mean difference of AIC between the intervention groups 
versus the control groups supports the notion that pharmacy-based interventions have a significant 
effect on lowering A1C levels in patients with diabetes. There is consistency between results of all 
randomized controlled trial with non-RTCs studies in our review, therefore all seven non-RCTs ;which 
were excluded from meta-analysis ; determined significant reduction of A1C level in intervention group 
relative to control group(49)(50)(51)(52)(53)(54)(55). 
According to the literature, there was one systematic review and meta-analysis which estimated the 
effect of pharmacist intervention on level of A1C in 2007(6). Machado M et al included 18 Randomized 
controlled trials and determined that pharmacist intervention decreased A1C level 0.62% in intervention 
group versus control group.  
Other research also demonstrated the significant effect of different types of community-based 
interventions such as behavioural/educational interventions and self-care management programming 
on lowering A1C levels in patients with diabetes.  Gary et al (56) conducted a meta-analysis to assess the 
effectiveness of behavioural/educational interventions in controlling diabetes. Among 18 randomized 
controlled trials, A1C was reduced by an average of 0.43% (56). Moreover, Ellis et al (57) assessed the 




were 0.32% lower in the intervention group compared with the control group. Improvements in 
lowering A1C averaging 0.36% were also found for patients receiving self-care management 
programming according to a meta-analysis conducted by Minet et al (58). Our results show a net 
reduction of A1C of 0.96%, which is higher than estimates from previous studies, focused on 
behavioural/educational and self-care management interventions. The results of this meta-analysis 
confirm that pharmacy-based interventions are effective in reducing A1C levels.  Since lowering A1C can 
help prevent diabetes–related complications, pharmacy-based interventions may help reduce some of 
this burden.  
In terms of BMI, this review showed that, pharmacy–based interventions are associated with significant 
reduction in BMI in intervention group compared with control group (0.61: 95% CI 0.20 to 1.03 p=0.000).  
Comparatively, other studies have reported a net mean reduction in BMI among patients with diabetes 
of less than 0.61 as a result of community interventions. For example, Liang Chen et al (59) conducted a 
meta-analysis to assess the effectiveness of a lifestyle intervention on patients with type 2 diabetes. 
Results demonstrated that the standardized difference in means of change from baseline to the time of 
the last follow-up significantly favoured the intervention group compared to the control group in BMI (-
0.29; 95% CI -0.52 to - 0.06, P = 0.014). Since overweight and obesity can increase an individual's risk of 
chronic complications of diabetes (60)(61) , lowering one’s BMI through pharmacy-based interventions 
could also have a significant role in reducing diabetes complications.   
Although result of meta-analysis among all randomized controlled trials show significant improvement 
in BMI, one retrospective, non-randomized clinical trial and one quasi-experimental study in our review; 
which were excluded from meta-analysis; demonstrated that, there is no significant relationship 
between improving BMI in intervention group compared with control group (50) (51), therefore type of 
study design might have great impact on result in this area. 
Regarding the effect of pharmacy –based intervention on quality of life, a review of the included studies 
showed that the type of questionnaire used, and follow-up duration have an impact on results. Review 
of evidence included in our analysis indicated that more robust improvements in quality of life were 
detected using generic questionnaires.  Average follow-up duration in studies, which report significant 
differences in quality of life between the intervention and control groups, is 10 months whereas; 
average follow-up for those studies reporting non-significant findings is about 6 months , this points to 




reviews that assessed the effect of pharmacy-based interventions on quality of life determined that lack 
of sensitive questionnaires could be one of the reasons behind observing non-significant findings in 
some included studies (3). Patient reported quality of life and its measurement are becoming 
increasingly important and hence there is a need for conducting more research in this area especially as 
different health care payment models proliferate creating a need for understanding how the different 
models affect patients’ quality of life. (62)(63). 
When considering health service utilization, type and level of evidence have great impact on the result. 
Since significant difference between two group were reported only in retrospective studies (48)(49)(54) 
rather than RCTs, there is lack of reliability of finding in this area. Overlay, the results of the review 
provided a mixed picture of the effect of pharmacy-based interventions on health care utilization and 




















(1) Evans GW KE. Strategies for reducing morbidity and mortality from diabetes through health-care 
system interventions and diabetes self-management education in community settings. Mortal Wkly Rep 
Recomm Reports 2011;50:1–5. 
(2) Wubben DP, Vivian EM. Effects of Pharmacist Outpatient Interventions on Adults with Diabetes 
Mellitus: A Systematic Review. Pharmacotherapy 2008;28:421–36. doi:10.1592/phco.28.4.421. 
(3) Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist Interventions in the Management of 
Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. J Manag Care Spec 
Pharm 2016;22:493–515. doi:10.18553/jmcp.2016.22.5.493. 
(4) g O’Donovan DO, Byrne S SL. The role of pharmacists in control and management of type 2 
Diabete s Mellitus; a review of the literatureTitle. J Diabetol 2011;2(1):6. 
(5) Santschi V, Colosimo AL, Chiolero A, Burnand B, Paradis G. Pharmacist interventions to improve 
cardiovascular disease risk factors in diabetes: A systematic review and meta-analysis of randomized 
controlled trials. Diabetes Care 2012;35:2706–17. doi:http://dx.doi.org/10.2337/dc12-0369. 
(6) Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist 
interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 
2007;41:1569–82. doi:10.1345/aph.1K151. 
(7) Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting 
items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. 
doi:10.1186/2046-4053-4-1. 
(8) Gerstein H, Swedberg K, Carlsson J, McMurray J. hemoglobin A1c level as a progressive risk 
factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart 
failure: Arch Intern Med 2008;168:1699–704. 




(10) Bakeera S, Wamala S, Galea S, State A, Peterson S, Pariyo G. Community perceptions and factors 
influencing utilization of health services in Uganda. Int J Equity Health 2009;8:25. doi:10.1186/1475-
9276-8-25. 
(11) Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with 
continuous response. J Clin Epidemiol 1992;45:769–73. doi:10.1016/0895-4356(92)90054-Q. 
(12) R. A, A. R. Effect of patient counseling on quality of life in type-2 diabetes mellitus patients in 
two selected South Indian community pharmacies: A study. Indian J Pharm Sci 2007;69:519–24. 
(13) M.O. A, C.V. U. The impact of pharmaceutical care intervention on the quality of life of nigerian 
patients receiving treatment for type 2 diabetes. Value Heal Reg Issues 2013;2:240–7. 
(14) Ali M, Schifano F, Robinson P, Phillips G, Doherty L, Melnick P, et al. Impact of community 
pharmacy diabetes monitoring and education programme on diabetes management: A randomized 
controlled study. Diabet Med 2012;29. doi:10.1111/j.1464-5491.2012.03725.x. 
(15) Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of 
pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol 
2009;67:547–57. doi:10.1111/j.1365-2125.2009.03391.x. 
(16) Cani CG, Lopes LD, Queiroz M NM. Improvement in medication adherence and self-management 
of diabetes with a clinical pharmacy program: a randomized controlled trial in patients with type 2 
diabetes undergoing insulin therapy at a teaching hospital. Clinics 2015;70(2):102–6. 
(17) Chung WW, Chua SS, Lai PSM, Chan SP. Effects of a pharmaceutical care model on medication 
adherence and glycemic control of people with type 2 diabetes. Patient Prefer Adherence 2014;8:1185–
94. doi:10.2147/PPA.S66619. 
(18) Chan C-W, Siu S-C, Wong CKW, Lee VWY. A pharmacist care program: Positive impact on cardiac 
risk in patients with type 2 diabetes. J Cardiovasc Pharmacol Ther 2012;17:57–64. 
doi:10.1177/1074248410396216. 
(19) Chen J-H, Huang-Tz Ou B, Tzu-Chieh Lin B, Edward Chia-Cheng Lai B, Yea-Huei Yang Kao B, Yang 
Kao Y-H. Pharmaceutical care of elderly patients with poorly controlled type 2 diabetes mellitus: a 




(20) Clifford RM, Davis WA, Batty KT, Davis TME. Effect of a pharmaceutical care program on vascular 
risk factors in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 2005;28:771–6. 
doi:10.2337/diacare.28.4.771. 
(21) Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu W-C. Pharmacist-Led Shared 
Medical Appointments for Multiple Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. 
Diabetes Educ 2011;37:801–12. doi:10.1177/0145721711423980. 
(22) Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of 
high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: A randomized controlled trial. 
Am J Manag Care 2005;11:253–60. 
(23) Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmacist-led patient 
education on glycemic control of type 2 diabetics: A randomized controlled trial. J Res Med Sci 
2011;16:43–9. 
(24) Fornos JA, Andrés NF, Andrés JC, Guerra MM, Egea B. A pharmacotherapy follow-up program in 
patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci 2006;28:65–72. 
doi:10.1007/s11096-006-9003-0. 
(25) Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care 
model on diabetes management. Ann Pharmacother 1996;30:238–43. 
(26) Jarab  a S, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of 
clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in 
Jordan. J Manag Care Pharm 2012;18:516–26. doi:2012(18)7: 516-526 (pii). 
(27) Jameson JP, Baty PJ. Pharmacist collaborative management of poorly controlled diabetes 
mellitus: a randomized controlled trial. Am J Manag Care 2010;16:250–5. 
(28) Jacobs M, Sherry PS, Taylor LM, Amato M, Tataronis GR, Cushing G. Pharmacist Assisted 
Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study. J Am Pharm Assoc 
2012;52:613–21. doi:10.1331/JAPhA.2012.10183. 
(29) Kjeldsen LJ, Bjerrum L, Dam P, Larsen BO, Rossing C, Søndergaard B, et al. Safe and effective use 




delivered by local pharmacies. Res Social Adm Pharm 2015;11:47–62. 
doi:10.1016/j.sapharm.2014.03.003. 
(30) Kraemer DF, Kradjan WA, Bianco TM, Low JA. A Randomized Study to Assess the Impact of 
Pharmacist Counseling of Employer-Based Health Plan Beneficiaries With Diabetes. J Pharm Pract 
2012;25:169–79. doi:10.1177/0897190011418513. 
(31) Krass I, Armour CL, Mitchell B, Brillant M, Dienaar R, Hughes J, et al. The pharmacy diabetes care 
program: Assessment of a community pharmacy diabetes service model in Australia. Diabet Med 
2007;24:677–83. doi:10.1111/j.1464-5491.2007.02143.x. 
(32) Lim PC, Lim K, Embee ZC, Hassali MA, Thiagarajan A, Khan TM. Study investigating the impact of 
pharmacist involvement on the outcomes of diabetes medication therapy adherence program Malaysia. 
Pak J Pharm Sci 2016;29:595–601. 
(33) Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP, et al. Effectiveness 
of a community pharmacist intervention in diabetes care: A randomized controlled trial. J Clin Pharm 
Ther 2011;36:602–13. doi:10.1111/j.1365-2710.2010.01218.x. 
(34) Mansell K, Evans C, Tran D, Sevany S. The association between self-monitoring of blood glucose, 
hemoglobin A1C and testing patterns in community pharmacies: Results of a pilot study. Can Pharm J 
(Ott) 2016;149:28–37. doi:10.1177/1715163515618420. 
(35) Mourão AOM, Ferreira WR, Martins MAP, Reis AMM, Carrillo MRG, Guimarães AG, et al. 
Pharmaceutical care program for type 2 diabetes patients in Brazil: A randomised controlled trial. Int J 
Clin Pharm 2013;35:79–86. doi:10.1007/s11096-012-9710-7. 
(36) Neto PRO, Marusic S, de Lyra Junior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, et al. Effect of a 
36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and 
hypertensive patients. J Pharm Pharm Sci 2011;14:249–63. 
(37) Obarcanin E, Kruger M, Muller P, Nemitz V, Schwender H, Hasanbegovic S, et al. Pharmaceutical 
care of adolescents with diabetes mellitus type 1: the DIADEMA study, a randomized controlled trial. Int 




(38) Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes 
mellitus: a randomized pharmacist intervention. Ann Pharmacother 2005;39:433–40. 
doi:10.1345/aph.1E438. 
(39) Planas LG, Crosby KM, Farmer KC, Harrison DL. Evaluation of a diabetes management program 
using selected HEDIS measures. J Am Pharm Assoc 2012;52:e130-8. doi:1484041 
(pii)\n10.1331/JAPhA.2012.11148 (doi). 
(40) Ramanath K V., Santhosh YL. Impact of clinical pharmacist provided patient education on QOL 
outcome in type II diabetes mellitus in rural population. Asian J Pharm Clin Res 2011;4:15–20. 
(41) Rothman RL, Malone R, Bryant B, Shintani AK, Crigler B, Dewalt DA, et al. A randomized trial of a 
primary care-based disease management program to improve cardiovascular risk factors and glycated 
hemoglobin levels in patients with diabetes. Am J Med 2005;118:276–84. 
doi:10.1016/j.amjmed.2004.09.017. 
(42) Sarkadi A, Rosenqvist U. Experience-based group education in Type 2 diabetes: a randomised 
controlled trial. Patient Educ Couns 2004;53:291–8. doi:10.1016/j.pec.2003.10.009. 
(43) Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed 
diabetes care services in a community health center. Am J Health Syst Pharm 2006;63:2116–22. 
doi:10.2146/ajhp060040. 
(44) Srirama S, Chacka LE, Ramasamya R, Ghasemia  a, Ravia TK, Sabzghabaee  a M. Impact of 
pharmaceutical care on quality of life in patients with type 2 diabetes mellitus. J Res Med Sci 
2011;16:412–8. 
(45) Suppapitiporn S, Chindavijak B, Onsanit S. Effect of diabetes drug counseling by pharmacist, 
diabetic disease booklet and special medication containers on glycemic control of type 2 diabetes 
mellitus: a randomized controlled trial. J Med Assoc Thai 2005;88 Suppl 4. 
(46) Taveira TH, Friedmann PD, Cohen LB, Dooley AG, Khatana SA, Pirraglia PA, et al. Pharmacist-led 
group medical appointment model in type 2 diabetes. Diabetes Educ 2010;36:109–17. 




(47) Wishah RA, Al-Khawaldeh OA, Albsoul AM. Impact of pharmaceutical care interventions on 
glycemic control and other health-related clinical outcomes in patients with type 2 diabetes: 
Randomized controlled trial. Diabetes Metab Syndr 2015;9:271–6. doi:10.1016/j.dsx.2014.09.001. 
(48) Brophy L, Williams A, Berman EJ, Keleti D, Michael KE, Shepherd M, et al. Collaborative DTM 
reduces hospitalization and healthcare costs in patients with diabetes treated with polypharmacy. Am J 
Manag Care 2014;20. 
(49) Chung N, Rascati K, Lopez D, Jokerst J, Garza A. Impact of a Clinical Pharmacy Program on 
Changes in Hemoglobin A1c, Diabetes-Related Hospitalizations, and Diabetes-Related Emergency 
Department Visits for Patients with Diabetes in an Underserved Population. J Manag Care Pharm 
2014;20:914–9. doi:10.18553/jmcp.2014.20.9.914. 
(50) Correr CJ, Melchiors AC, Fernandez-Llimos F, Pontarolo R. Effects of a pharmacotherapy follow-
up in community pharmacies on type 2 diabetes patients in Brazil. Int J Clin Pharm 2011;33:273–80. 
doi:10.1007/s11096-011-9493-2. 
(51) Johnson KA, Chen S, Cheng IN, Lou M, Gregerson P, Blieden C, et al. The impact of clinical 
pharmacy services integrated into medical homes on diabetes-related clinical outcomes. Ann 
Pharmacother 2010;44:1877–86. doi:10.1345/aph.1P380. 
(52) McAdam-Marx C, Dahal A, Jennings B, Singhal M, Gunning K. The Effect of a Diabetes 
Collaborative Care Management Program on Clinical and Economic Outcomes in Patients with Type 2 
Diabetes. J Manag Care Spec Pharm 2015;21:452–68. doi:10.18553/jmcp.2015.21.6.452. 
(53) Skinner JS, Poe B, Hopper R, Boyer A, Wilkins CH. Assessing the Effectiveness of Pharmacist-
Directed Medication Therapy Management in Improving Diabetes Outcomes in Patients With Poorly 
Controlled Diabetes. Diabetes Educ 2015;41:459–65. doi:10.1177/0145721715587563. 
(54) Spence MM, Makarem AF, Reyes SL, Rosa LL, Nguyen C, Oyekan EA, et al. Evaluation of an 
outpatient pharmacy clinical services program on adherence and clinical outcomes among patients with 





(55) Wertz D, Hou L, DeVries A, Dupclay LJ, McGowan F, Malinowski B, et al. Clinical and economic 
outcomes of the Cincinnati Pharmacy Coaching Program for diabetes and hypertension. Manag Care 
2012;21:44–54. 
(56) Gary TL, Genkinger JM, Guallar E, Peyrot M, Brancati FL. Meta-analysis of randomized 
educational and behavioral interventions in type 2 diabetes. Diabetes Educ 2003;29:488–501. 
doi:10.1177/014572170302900313. 
(57) Ellis SE, Speroff T, Dittus RS, Brown A, Pichert JW, Elasy TA. Diabetes patient education: A meta-
analysis and meta-regression. Patient Educ Couns 2004;52:97–105. doi:10.1016/S0738-3991(03)00016-
8. 
(58) Minet L, Møller S, Vach W, Wagner L, Henriksen JE. Mediating the effect of self-care 
management intervention in type 2 diabetes: A meta-analysis of 47 randomised controlled trials. Patient 
Educ Couns 2010;80:29–41. doi:10.1016/j.pec.2009.09.033. 
(59) Chen L, Pei J-H, Kuang J, Chen H-M, Chen Z, Li Z-W, et al. Effect of lifestyle intervention in 
patients with type 2 diabetes: A meta-analysis. Metab Exp 2015;64:338–47. 
doi:10.1016/j.metabol.2014.10.018. 
(60) Hramiak I, Leiter LA, Paul TL UE. Assessment of Obesity and its Complications in Adults. Can Med 
Assoc Journal 2007;178:36–9. 
(61) Morrison K CJC evaluation of obese children and adolescents. Clinical evaluation of obese 
children and adolescents. Can Med Assoc J 2007;176(8):45–9. 
(62) Saver BG, Martin SA, Adler RN, Candib LM, Deligiannidis KE, Golding J, et al. Care that Matters: 
Quality Measurement and Health Care. PLoS Med 2015;12. doi:10.1371/journal.pmed.1001902. 






CHAPTER 4-Patient-level micro-simulation model for evaluating the future potential cost–
effectiveness of pharmacy-based interventions in the control and management of diabetes-
related complications in Canada 
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In this chapter, I use an agent-based model along with system dynamics to model the progression of 
four diabetes-related complications and evaluate the cost–effectiveness of pharmacy-based 
interventions in the control and management of diabetes-related complications in Canada over a life-
time horizon. Findings of this study provide strong evidence for Canadian health policymakers to 
implement potential cost-effective pharmacy-based interventions for the control and management of 














Diabetes is one of the growing non-communicable diseases worldwide (1-3) and is a leading cause of 
death in most developing countries (4) Diabetes is also associated with a number of micro-vascular and 
macro-vascular complications (5-8) which lead to premature death, reduce individuals’ quality of life, 
and economic burden (3, 5-9). Due to high economic burden of diabetes in Canada (10-12), there is an 
opportunity to reduce this expenditure through the adoption of diabetes management interventions 
such as pharmacy-based ones. Pharmacy-based interventions include a wide range of services, all with 
the common aim of giving diabetes patients greater control and management over their disease (13-17). 
Rising health care costs, limitations on available health care resources, and debates over the 
comparative effectiveness of diabetes management strategies has led to an increased interest in 
developing analytic models that can evaluate the future potential cost-effectiveness of such 
intervention. These models compliment clinical trials, which typically provide data on intermediate 
outcomes like HbA1c, SBP, and LDL. Data from clinical trials can then be used to populate analytic 
models, and provides a basis for predicting long-term health outcomes, like life-years saved or QALYs 
gained.  
This study aims to evaluate the future potential cost effectiveness of pharmacy-based interventions for 
diabetes management in Canada. In order to conduct this evaluation, we estimate life time outcome 
and quality-adjusted life expectancy among diabetes patients who experience diabetes-related 
complications (heart failure, stroke, amputation, and blindness) or diabetes-related death.   
4.2. Methods 
4.2.1. Model Overview  
We evaluated the future potential cost-effectiveness of pharmacy-based interventions for patients with 
diabetes compared to usual care. Intermediate outcome of intervention was modeled as reduction of 
hemoglobin A1C (HbA1c) level, body mass Index (BMI), systolic blood pressure (SBP), and low-density 
lipoproteins (LDL) as most important risk factors of four common diabetes-related complications 
including heart failure, stroke, amputation and blindness.  Cost was quantified as the annual cost of 
heart failure, stroke, amputation and/or blindness among diabetes patients; and, the cost associated 
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with pharmacy-based interventions borne by society.  To fully capture the effect of the intervention, we 
extrapolated the potential effects of intervention in relation to cost, health outcomes, and health-
related quality of life (HRQoL) over the next 50 years by calculating the incremental cost per QALY 
gained of pharmacy-based intervention versus usual care in base case scenario. This model considered 
both costs and health effects, which were adjusted by discount rate of 3% according to the Canadian 
Agency for Drugs and Technologies in Health (CADTH) guideline (18). Both deterministic and Monte 
Carlo probabilistic sensitivity analysis were used to estimate uncertainty around results. Detail of model 
overview are shown in Figure 4.1 
4.2.2. Model Structure  
Using Anylogic software package 8.2.3, a hybrid simulation model was developed, which included agent-
based and system dynamics. Agent-based modeling (ABM) enables to simulate more complex 
interactions and processes associated with chronic disease. Thus, this technique is very suitable for 
incorporating individuals with different risk factors and health behavior characteristic and evaluating the 
impact of adjusting risk factors on the better control and management of diabetes (19). 
We captured four major diabetes-related complications progresses among patients with heterogeneous 
characteristics through state-transition formalism as state charts in ABM model. Also, we used a system-
dynamic approach to estimate accumulated costs and QALYs over time (Figure 4.2-4.3).  
The simulation model mimicked a multistage study and was populated by data from the Survey on Living 
with Chronic Diseases in Canada (SLCDC). This data was used to build an individual-level micro-
simulation model predictive of diabetes-related complications (heart failure, stroke, blindness, and 
amputation) and death, and the associated health care cost and QALYs in the presence and absence of 
pharmacist-based intervention. Within the model, a set of attributes known to be associated with 
diabetes-related complications was assigned to each person. The attributes were also subject to a set of 
rules (i.e. transition probabilities) and states reward (i.e. cost and utility). All parameters are shown in 







Figure 4.1. Flow chart of simulation 
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Figure 4.3. System dynamic model architectures in Anylogic 
 
 
4.2.3. Data source 
4.2.3.1. Diabetes Risk Factors  
To estimate a diabetes patient’s progression from complication free to a complication ridden state, we 
used the UK Prospective Diabetes Study (UKPDS) outcome model (20). This model was developed using 
data from 5,102 patients followed over a 20-year trial period, and 4,031 survivors followed over a 10-
year post-trial monitoring period. The UKPDS model allowed us to estimate the main risk equations for 
developing the four diabetes–related complications of interest in our study: heart failure, stroke, 
amputation and blindness. It also allowed us to derive parametric proportional hazard models predictive 
of absolute risk factors of diabetes-related complications, including: age, sex, duration of diabetes, 
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smoking status, body mass index (BMI), HbA1c, SBP, LDL, high density lipoprotein cholesterol (HDL), 
heart rate, presences of micro- or macro-albuminuria (MICLAB), atrial fibrillation (ATFIB), peripheral 
vascular disease (PVD), white blood cell count (WBC), amputation history, heart failure history, stroke 
history, blindness history, renal disease history, and ulcer foot history. UKPDS model used a Weibull 
proportional hazards regression to calculate the occurrence of the composite outcome, which combined 
both fatal and non-fatal events (20). 
We extracted baseline characteristics from the 2,931 diabetes patients included in the SLCDC survey 
2011 (Table 4.1) and risk equations for each of the baseline variables were taken from the UKPDS. This 
allowed us to estimate transition probabilities of developing diabetes-related complications (See 
Appendix D). For some of the risk questions which the corresponding baseline variables were not 
available in the SLCDC survey, we estimated baseline variables based on age and sex specific. 
4.2.3.2. Mortality  
To estimate progression from a complication-free state to a state where at least one of the four major 
complications or death have occurred, our analysis considered four equations for calculating risk of 
mortality based on the UKPDS model. The first equation estimates the probability of death in the first 
year following an occurrence of heart failure, stroke, amputation or blindness, based on a logistic 
regression. Similarly, the second equation is based on logistic regression. It estimates the risk of 
diabetes-related mortality among patients with a history of any one of these complications in all 
subsequent years. The third equation is based on multivariate Gompertz proportional hazards survival 
models, and estimates death among diabetes patients without any history of diabetes-related 
complications. In this equation, death is the result of a cause unrelated to diabetes. The fourth equation 
is slightly more nuanced, and estimates death among diabetes patients without complication who had a 
history of co-morbidities (20). Transition probabilities of death were calculated from these equations 
based on logistic regression and Gompertz proportional hazards model (See Appendix E).  
4.2.3.3. Treatment Effect  
The impact that pharmacy-based interventions have on four major risk factors associated with diabetes-
related complications was extracted from recent systematic reviews and meta-analyses. The four major 





From baseline to the last follow-up 12 months later, the standardized absolute mean difference in the 
reduction of HbA1c was significantly more favorable in the pharmacy- based intervention group, then in 
the control group (0.96%; 95% CI 0.71:1.22, P<0.001) (13). 
Body Mass Index (BMI)  
From baseline to the last follow-up 12 months later, the standardized absolute mean difference in the 
reduction of BMI units was 0.61 (95% CI 0.20: 1.03, P=0.000) in favor of the pharmacy-based 
intervention group (13).  
Systolic Blood Pressure (SBP)  
In comparison to the control group, there were significant reductions in SBP among diabetes patients in 
the pharmacy-based intervention group after a 12-month period (-6.2 mmHg (95% CI -7.8 to -4.6)) (17).  
Low Density Lipoprotein (LDL) Cholesterol   
In comparison to the control group, there were significant reductions in LDL cholesterol among diabetes 
patients in the pharmacy-based intervention group after a 12-month period (-11.7 mg/dL (-15.8 to -7.6)) 
(17).  
4.2.3.4. Health Utilities  
We assumed that utility values derived from the American population are relevant to the Canadian 
population. We quantified HRQoL for a set of health states of interest based on American catalogue of 
EQ-5D utility values (21). Health states of interest include: following a stroke, following heart failure, 
after the age of 70 years. Following a stroke, the resulting utility was 0.694. Following heart failure, the 
resulting utility was 0.636. After the age of 70, a utility decrement of 0.00029 per year was applied to all 
years.  
Under the assumption that utility values derived from the United Kingdom population are relevant to 
Canada, the UKPDS outcome model was used to estimate HRQoL for a set of health states of interest. 
Health states of interest include: following an amputation, and following blindness. Following 
amputation, a utility decrement of 0.520 was applied. Following blindness, a utility decrement of 0.726 
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was applied. A weight of zero was assigned to death. If applicable to incorporate the effect of 
concurrent complications, a multiplicative method approach was applied (21). 
4.2.3.5. Cost of Treating Diabetes-Related Complications  
Health care resource utilization and their costs associated with the management of diabetes-related 
complications were extracted from the Ontario Ministry of Health and Long-Term Care (22). Total costs 
of patients with diabetes and patients with complications were quantified in terms of hospitalizations, 
outpatient visits, emergency visits, home care and long-term management costs. Costs were inflated to 
the value of the 2016 Canadian dollar using the health component of the Canadian Consumer Price 
Index. On average, the annual cost for patients without diabetes-related complications was $2,075 (22). 
The estimated costs for each of the four diabetes-related complications in the first year they occur, and 
for all subsequent years are shown in Table (4.1).  
4.2.3.6. Intervention Costs 
To estimate the cost of pharmacy-based interventions, costs incurred by the implementation of the 
MedsCheck program served as a benchmark. This program is a pharmacy-based intervention targeted at 
diabetes patients in Canada (23). Based on the current fee schedule of the MedsCheck program in 
Alberta, the unit cost of the first annual consultation was determined to be $75 CAD, the unit cost of 
each subsequent consultation within that year was $25 CAD, and the unit cost of long-term follow-up 
was $75 CAD (23). 
The indirect costs associated with wait-times and travelling related to pharmacy-based interventions 
were added to the model. Based on the MedsCheck program, the total time lost for pharmacy 
consultation was 2 minutes for waiting and 20 minutes for the duration of the consultation (24). Based 
on these estimates, we calculated an opportunity cost. The total time lost was multiplied by the number 
of pharmacy consultations in one year assuming that the entire study population would be the recipient 
of pharmacy-based interventions. This number was then multiplied by $24.96 CAD or the average wage 
per hour in Canada (25).      
Based on data from Geographic Accessibility of Community Pharmacies, the cost of travelling to a 
pharmacy was estimated using the average travel time among patients who visited a pharmacist (26), 
and the mean fuel cost per kilometer (km) of $0.12/km CAD (27).  
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4.2.4. Incremental Cost-Effectiveness Analysis  
An incremental analysis combined the joint estimates of costs and effects across the baseline scenario 
and the intervention scenario. The result of this analysis yielded the point estimate of the mean ICER. 
The ICER was calculated as the difference in costs between baseline and intervention divided by the 
difference in effects (i.e. QALYs) between baseline and intervention.  
Measures of variance for the joint incremental costs and effects were obtained using Monte Carlo 
simulation and presented graphically using the cost-effectiveness plane. In order to convert health 
outcome (QALYs) to common metric as dollar, the net monetary benefit (NMB) was calculated. The NMB 
is equal to the QALYs multiplied by the ceiling ratio (CR) of willingness to pay (WTP) per QALY minus the 
strategy costs. 
NMB = (QALYs * CR) – Costs 
4.2.5. Sensitivity Analysis 
Both probabilistic and deterministic sensitivity analyses were conducted to explore the model’s 
uncertainty. The deterministic sensitivity analysis was conducted to investigate the impact of key 
assumptions and parameter values on the base-case analysis, including discount rate, time horizon, and 
treatment effect. The probabilistic sensitivity analyses were modeled through Monte Carlo simulation. 
Uncertainty in each of the underlying modeling parameters were characterized by assigning probability 
distribution to point estimates, and the model was run for 10,000 times for baseline estimate. Results 
were presented as plotted around point estimates of ICER on Incremental cost effectiveness plane. 
Table 4.1. Microsimulation Model Parameters 
Baseline Characteristic    
Mean Age 64 SLCDC-DM 
Sex (Female)  42.71% SLCDC-DM 
Duration 20 SLCDC-DM 
BMI 27.09 SLCDC-DM 
HbA1c 7.6 SLCDC-DM 
Smoke 15.8% SLCDC-DM 
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Cost of Complication   
Heart Disease (First Year of Event)  $17,813 ODEM/CADTH 
Heart Disease (Subsequent Years) $4,994 ODEM/CADTH 
Stroke (First Year of Event) $26,523 ODEM/CADTH 
Stroke (Subsequent Years) $3,680 ODEM/CADTH 
Blindness (First Year of Event) $3,258 ODEM/CADTH 
Blindness (Subsequent Years) 2,322 ODEM/CADTH 
Amputation (First Year of Event) $41,143 ODEM/CADTH 
Amputation (Subsequent Years) $5,683 ODEM/CADTH 
Discount rate  0.03 CADTH 
Cost of Intervention   
MedsCheck Program (First Year) $157.18 CFPNET 
MedsCheck Program (Subsequent Years) $107.18 CFPNET 
Utility Parameters   
Diabetes with no complication 0.758 Sullivan PW(2005) 
Heart Disease 0.639 Sullivan PW(2005) 
Stroke 0.694 Sullivan PW (2005) 
Blindness 0.726 PM. Clarke et al 
Amputation 0.520 PM. Clarke et al 
Utility Decrement (After 70 Year) 0.00029 Sullivan PW (2005) 
Treatment Effect   
HbA1c risk reduction by intervention  0.96% M. Yaghoubi (2017) 
BMI risk reduction by intervention  0.61 M. Yaghoubi (2017) 
SBP risk reduction by intervention 6.2 Santschi V (2012) 
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The primary objective of the simulation model was to calculate the accumulated events of four diabetes-
related complications over the lifetime of 2,931 patients with specific baseline characteristics and risk 
factors. As shown in Table 4.2, over the 50 years of usual care patients, there were 206 heart failures, 
242 strokes, 29 amputations, and 51 cases of blindness. In comparison, over the lifetime horizon of 
pharmacy-based intervention patients, 159, strokes, 19 heart failures, 24 amputations and 29 cases of 
blindness events could be averted according to our model. The model also predicted 155 fewer death 
associated with complications among intervention groups compared to usual care over the lifetime 
horizon.  The cumulative cost was discounted at 3% per year. Over 50 years, the cumulative discounted 
cost for usual care patients was $30,159,963 CAD total or $10,289 CAD per patient. In comparison, the 
cumulative discounted cost for pharmacy-based intervention patients was only slightly higher, at 
$33,904,268 CAD total or $11,567 CAD per patient.   
The pharmacy-based intervention was associated with 0.42 additional life-years and 0.32 additional 
QALYs per patient in comparison to usual care. Cumulatively, the pharmacy-based intervention was 
associated with 15,207 QALYs or 5.18 per patient, whereas usual care was associated with 14,254 QALYs 
or 4.8 per patient (Table 4.2)  
Improvements in HbA1c, BMI, SBP and LDL expected to result from the pharmacy-based interventions 
reduced the number of diabetes-related complications over the lifetime horizon. This reduction led to 
the addition of 0.32 QALYs, and an ICER of $3,929 CAD per QALY compared to usual care. Further, the 
NMB of the pharmacy-based intervention was calculated to be $247,433 CAD based on (5.18*50,000) – 
(11,567).   
Despite changes to the ICERs across the one-way sensitivity analyses, the pharmacy-based intervention 
remained cost-effective. When the lifetime horizon was shortened to 20 years, the ICER changed to 
$2,831.9 CAD. When the lifetime horizon was shortened to 20 years and a 1.5% discount was applied to 
costs and effects, ICER changed to $4,923. When the anticipated effect of the intervention on HbA1c, 
BMI, LDL, and SBP was lowered, ICER changed to $4,580 (Table 4.2).  Our probabilistic sensitivity 
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analyses involved varying all the parameters’ uncertainties at the same time using Monte Carlo 
simulation. Then, 10,000 samples of cost and QALYs were used for both the usual care and intervention 
groups (Figure 4.4). As shown in the cost-effectiveness acceptability curve plot, 92% of iterations 
remained within a cost-effectiveness threshold of $50,000 per QALY (Figure 4.5).  
Table 4.2. Result of Microsimulation Model  
 Usual care Pharmacist Intervention Difference 
Accumulated number of heart failure  206 187 19 
Accumulated number of strokes  242 83 159 
Accumulated number of amputations  29 5 24 
Accumulated number of blindness  51 22 29 
Accumulated number of deaths associated with events 401 246 155 
Life years 18,853 20,099 1,246 
Quality Adjusted Life Years (QALYs) 14,254 15,207 953 
QALYs per patients 4.8 5.18 0.32 
Discounted Costs $30,159,973 $33,904,168 $3,744,195 
Discounted Costs per patients $10,289 $11,567 $1277 
Undiscounted Costs $40,846,595 $46,355,459 $5,508 
ICER (Discounted)    $3928 
ICER (Undiscounted)   $5779 
NMB   $247,433 
One-way sensitivity Analysis    
ICER (20 Years horizon)   $2831 
ICER (Low discount rate)   $4923 
ICER (Reduce treatment effect)   $4580 
 











Using a patient-level micro-simulation model, the future potential cost-effectiveness of pharmacy-based 
intervention in the control and management of four diabetes-related complications was analyzed. 
Across a 50-year lifetime horizon, the intervention proved to be a cost-effective strategy when 
compared to the usual care (status quo) diabetes patients across Canada receive. The ICER remained 
below the cost-effectiveness threshold across both deterministic and probabilistic sensitivity analyses. 
This suggests that the implementation of pharmacy-based interventions could yield consistent results. 
This consistency is encouraging, especially in the context of the Canadian health care system where 
pharmacists’ scope is impacted by the jurisdiction in which they practice (36-37).  
The treatment effect of pharmacy-based interventions was assumed to be low in our analysis. The effect 
on HbA1c, BMI, SBP and LDL was set at 0.71, 0.20, 4.6, and 7.6 respectively. Based on these values, the 
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intervention resulted in the addition of 670 more QALYs compared to status quo. Our analysis included a 
wide range of services that made up an integrated pharmacy-based intervention. However, the results 
of a recent meta-analysis suggest that diabetes education delivered by pharmacists coupled with 
pharmaceutical care maximizes the effectiveness of such services (28). HbA1c was lowered by 0.86 and 
SBP was lowered by 4.94 when this scheme was followed (28). When our model was adjusted in 
accordance with this specific type of pharmacy-based intervention, the result did not change. Further 
research must be conducted to corroborate these findings, but this result suggests that pharmacy-based 
intervention could be effective in even the most resource limited settings.  
Our results did change, however, when the discount rate and time horizon were reduced. In these 
scenarios, the pharmacy-based intervention group gained 1,031 and 1,112 QALYs respectively.  These 
results highlight that this intervention will operate across jurisdictions and across patient lifespans.   
Our findings add to the literature and support previous economic evaluations of simulated community 
care programs for diabetes patients in Canada and around the world. Another Canadian patient-level 
microsimulation mode, the Ontario Diabetes Economic Model (ODEM), suggested that the incremental 
cost-effectiveness per QALY of a multidisciplinary management program was $5,203 over 10 years (22). 
Pharmacy-based interventions have also proven to be cost-effective in reducing risk factors, like 
hypertension, associated with diabetes-related complications in Canadian patients (29). This mirrors the 
reductions in risk factors reported in the present study. Further, a Markov cost-effectiveness model 
evaluated pharmacy-based interventions in Kaiser Permanente Northern California and results 
demonstrated saving of $6,364 over the lifetime of a single diabetes patient; prevent cardiovascular 
disease among diabetes patients; and, is less expensive and more effective than usual care over a 10-
year time span (30). Again, these positive results compliment the findings from present study. By adding 
to this literature, provincial governments and health professionals are given a source from which to 
draw when creating evidence-based practices for the treatment of diabetes patients.     
Additionally, our findings compliment previous economic evaluations conducted in real time using 
emerging patient data. Over 36-months, a randomized controlled clinical trial estimated the ICER per 
QALY of pharmaceutical care used to manage diabetes and hypertension among elderly patients (31). 
This analysis demonstrated that pharmaceutical care did not significantly increase the cost of direct 
health care but did significantly improve health outcomes (31). More specifically, the ICER per QALY 
($53.50) gained reflected favorably on its cost-effectiveness (31). In a North American context, the cost-
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effectiveness of pharmacy-led drug management education programs (DMEP) has been evaluated. 
Results from these evaluations suggest that DMEPs are cost-effective relative to usual care, and avert 
$39 USD per day spends on glycemic symptoms among diabetes patients (32). The results from our 
simulated model are consistent with findings from clinical trials, and operational education programs. 
This consistency reinforces the idea that pharmacy-based interventions could be an effective means to 
manage diabetes and its related complications.  
Lastly, our findings do not vary even when compared to the results yielded by different modeling 
techniques. When a discrete-event simulation model was used, alternative treatment strategies, like 
pharmacy-based interventions, were associated with enhanced long-term health outcomes among 
diabetes patients (33). Similarly, when a Markov cohort analysis was conducted to assess the cost-
effectiveness of Continuous Glucose Monitoring (CGM) technology compared to self-monitoring, CGM 
led to an expected improvement of 0.52 QALYs and was cost-effective in 70% of the Monte Carlo 
simulations (34). When a decision tree model was used to estimate the cost-effectiveness of pharmacy-
based ophthalmology screenings compared to in-person examinations, the ICER was $314 CAD per 
additional case detected, and $73 CAD per additional case correctly diagnosed (35).  
Also, in another study authors used a modified Sheffield T1D policy model to simulate T1D complication 
and estimate cost effectiveness of continuous Glucose monitoring in diabetes trial consist of 158 
patients. Result of this analysis demonstrated that, continuous glucose monitoring led to an ICER of 
$98,000 and not only improve HbA1c controlling but also is cost –effective intervention in threshold of 
$100,000 in USA. Lastly an economic model was developed by Houle SK and et al (37) to estimate the 
effect of a pharmacist- based hypertension management program on economic burden of health care 
system. Results of this study determined that, this intervention could save $115 per patient for a 
program lasting one year (37).  
Overall, our finding suggests that pharmacy-based intervention could be a cost-effective intervention to 
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CHAPTER 5- CONCLUSIONS AND POLICY IMPLICATIONS 
 
5.1.Summary of findings 
 
This thesis aimed to address three research questions: (1) the prevalence of diabetes-related 
complications and determinants associated with them; (2) the effectiveness of pharmacy-based 
interventions on the control and management of diabetes; and, (3) the cost-effectiveness of pharmacy-
based interventions if implemented to manage health outcomes associated with diabetes-related 
complications.   
 
Chapter 2 of this thesis estimated the prevalence of diabetes-related complications identified on the 
SLCDC-DM-2011, and identified associations between these complications and select determinants. 
Overall, our findings indicate that, in Canada, the majority of diabetes patients experience complications 
related to their condition. High blood pressure, cataracts, poor circulation, and heart disease are among 
the most common complications. Patients were more likely to have at least one complication when they 
were older, had diabetes for more than 10 years, were unemployed, had an unhealthy BMI, and had a 
high level of A1C. Other determinants, including sex, marital status, education, income, and physical 
activity, were also found to be significantly associated with specific diabetes-related complications. 
These findings support and extend the work of others who have found established associations between 
determinants and diabetes-related complications (1-8).  
This chapter also highlighted that socio-economic determinants including marital status, education and 
income could be protective factors against some micro-vascular and macro-vascular complications. Our 
findings also confirm that low levels of physical activity and high levels of HbA1C were the most common 
risk factors for diabetes-related complications among Canadian patients. However, a 
prospective/longitudinal study design is needed to explore the effect of self-monitoring behaviour on 
the progression of diabetes–related complications. Since diabetes-related complications can be largely 
prevented or delayed through the mitigation of various risk factors, prevention strategies should target 
some of the risk factors identified. 
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Chapter 3 of this thesis calculated the pooled effect of pharmacy–based interventions on the control 
and management of diabetes after conducting a systematic review and meta-analysis. Interventions in 
the reviewed studies included patient education and counselling interventions focused on self-
management, self-monitoring, lifestyle and diet modification, medication adherence and awareness of 
the risk of developing diabetes-related complications. Results from the meta-analysis suggested that 
pharmacy-based interventions have a significant effect on decreasing HbA1C and lowering BMI; 
however, the effect on quality of life and health care utilization is still not clear. Timing, duration of 
pharmacy-based interventions, and duration of follow-up are likely to affect the assessed results of 
interventions in the reviewed studies. Population characteristics, like severity of illness, age and gender, 
could have also affected the assessed effectiveness of interventions in the studies. We used a random-
effect model to account for heterogeneity across studies. After excluding some heterogeneous studies, 
the results of influence analysis support the positive impact of pharmacy-based interventions on 
minimizing the effects of two major risk factors associated with diabetes-related complications. There is 
consistency between findings of this chapter with evidence in the literature (9-14). However, further 
investigation of the effects of pharmacy-based interventions on health care utilization and quality 
adjusted life years is warranted.   
Chapter 4 of this thesis presents novel findings about diabetes-related complications in Canada 
calculated by an individual level micro-simulation model. Using this model, the future potential cost-
effectiveness of a pharmacy-based intervention in the control and management of four diabetes-related 
complications was analyzed. Across a 50-year lifetime horizon, the intervention proved to be a cost-
effective strategy when compared to the usual care (status quo) diabetes patients across Canada 
receive. The ICER remained below the cost-effectiveness threshold across both deterministic and 
probabilistic sensitivity analyses. This suggests that the implementation of pharmacy-based 
interventions could yield consistent results. This consistency is encouraging, especially in the context of 
the Canadian health care system where pharmacists’ scope is impacted by the jurisdiction in which they 
practice (15, 16). 
5.2. Conclusion  
Canadian health policymakers should afford consideration to pharmacy-based interventions in the 
management of diabetes and its related complications. Through the expansion of education-based 
services by community pharmacies, there is the potential to reduce the incidence of diabetes-related 
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complications, and death resulting from diabetes. This is an important avenue that should not be 
overlooked, especially because it offers a solution to the growing and complex problems caused by 
diabetes.  
5.3. Thesis limitations 
 
This thesis has a number of limitations. In chapter 2, the cross-sectional design of the SLCDC-DM-2011 
used means that causal relationships between patient characteristics and diabetes-related 
complications may not be accurately depicted. Further, patients were asked to self-report their survey 
response, and thus there is an increased of risk of recall bias. Lastly, our ability to access data on other 
types of diabetes-related complications not reported on the SLCDC-DM-2011 was restricted. Despite, 
these limitations, the findings are relevant because they provide a comprehensive quantitative analysis 
of diabetes-related complications that were included on Canada’s SLCDC-DM-2011. 
In chapter 3, it was not possible to conduct a meta-analysis on quality of life and/or health care 
utilization. This is because of the different instruments and methodologies used across studies. In the 
quantitative meta-analysis that we did conduct, we were only able to considered two clinical outcomes; 
FBG, blood pressure, and cholesterol levels were not included because they were not consistently 
reported in the reviewed studies. Moreover, it was necessary to use BMI to predict one of the clinical 
outcomes, obesity. However, this proxy may not be the most accurate, as waist circumference has been 
deemed the better indicator. Despite this, waist circumference was not consistently reported across the 
reviewed studies, and so we were unable to predict the effect of pharmacy-based interventions on 
obesity using this measure.  
I would also like to acknowledge the limitations in the micro-simulation model presented in chapter 4. 
First, individual-level data was required for all included parameters, and some of the input variables had 
to be assumed based on the literature. Second, there is dearth of evidence describing the treatment 
effect of pharmacy-based interventions over the long-term. Consequently, we assumed that treatment 







As health care systems evolve with the changing health demands of the Canadian population, evidence 
will be required to inform best practices. Diabetes and its related complications are an example of one 
such demand that has emerged in the Canadian health landscape and will continue to grow. 
Importantly, this thesis highlights potential areas for future research that will fill the gaps and allow for a 
more seamless adoption of effective solutions. In chapter 2 of this thesis, the need for prospective and 
longitudinal studies was identified. Prospective and longitudinal studies will allow for the causal 
relationship between diabetes-related complications and select determinants to be explored. In chapter 
3, we identified a lack of high-quality evidence that assesses the effect of pharmacy-based interventions 
on quality of life and health care utilization. To fill this gap, more clinical trials should be that include 
these outcome variables. The results presented in chapter 4 provide valuable information for 
policymakers trying to implement pharmacy–based interventions that are effective in the control and 
management of debates. This information must be supplemented by future research that uses different 
types of simulation models. Discrete event simulation modelling, for example, could be used to predict 
the time that corresponds to the emergence of risk factors and the emergence of a major diabetes–
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Appendix B. Multivariable  regression result of each specific complication  







                                                                               
        _cons     .0210345   .0189868    -4.28   0.000     .0035811      .12355
               
           4      1.194963   .9366151     0.23   0.820      .256851    5.559393
           3      2.243798   .8140447     2.23   0.026     1.101385    4.571183
           2      .8049554   .3489874    -0.50   0.617     .3439208    1.884018
          a1c  
               
           4      .3243938   .1818133    -2.01   0.045     .1080543    .9738744
           3      .2698428   .1782128    -1.98   0.047     .0738805    .9855796
           2      .2567846   .1667788    -2.09   0.036     .0718306      .91797
   checkingbp  
               
           4      2.843621   1.553326     1.91   0.056     .9739932    8.302093
           3       .760281   .4243995    -0.49   0.624     .2543702    2.272386
           2      1.277686   .4504568     0.70   0.487     .6398863    2.551205
   checkingbs  
               
    2.insulin     1.291674   .4922932     0.67   0.502     .6116366    2.727798
               
           3      2.522228   1.108385     2.11   0.035     1.065239    5.972025
           2      1.972112   .9717408     1.38   0.168     .7502326    5.184027
      faindex  
               
2.durationofd      .780457   .2688567    -0.72   0.472     .3971024    1.533894
               
           4      .9385057   .4124862    -0.14   0.885     .3963167    2.222447
           3      .2961599   .2512792    -1.43   0.152     .0560761    1.564138
           2      .4769703   .2688045    -1.31   0.189     .1579153    1.440651
    education  
               
     2.income     .5290378   .2115766    -1.59   0.112     .2414424    1.159204
               
           3      7.196824   3.665775     3.87   0.000     2.650017    19.54489
           2      2.128858   .8076917     1.99   0.047     1.011482     4.48059
   employment  
               
           3       2.17416   1.686721     1.00   0.317      .474715    9.957498
           2      2.383798   1.802279     1.15   0.251     .5410459    10.50279
       agecat  
                                                                               
       stroke   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
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        _cons     .0705359   .0655938    -2.85   0.004     .0113828    .4370921
               
           4      .6398045   .4864495    -0.59   0.557     .1440057    2.842594
           3      1.654164   .4460172     1.87   0.062      .974748    2.807143
           2      1.435761   .3739832     1.39   0.165     .8613806    2.393145
          a1c  
               
           4      .4078491   .1663699    -2.20   0.028     .1832373    .9077898
           3       .631729   .3188761    -0.91   0.363      .234718     1.70026
           2      .3870029   .1724204    -2.13   0.033     .1615076    .9273324
   checkingbp  
               
           4      1.474431   .5540345     1.03   0.302     .7055588    3.081172
           3      1.182648   .4958849     0.40   0.689     .5196079    2.691755
           2      1.054274   .2738915     0.20   0.839       .63336    1.754915
   checkingbs  
               
    2.insulin     1.533165   .3840609     1.71   0.088      .937993    2.505984
               
           3      2.232991    .746552     2.40   0.016     1.159018     4.30213
           2      1.598382   .5456725     1.37   0.170     .8182163    3.122433
      faindex  
               
           5      .6215486   .2250601    -1.31   0.189     .3055096    1.264519
           4      .8166909    .364404    -0.45   0.650     .3403825    1.959513
           3      .6654454   .2166299    -1.25   0.211     .3513994    1.260155
           2      .4162366   .2612533    -1.40   0.163     .1215272    1.425631
    typeofsmk  
               
   2.bmiclass     .7324904   .2110057    -1.08   0.280     .4163069    1.288814
2.durationofd     1.798487   .4117312     2.56   0.010     1.147868    2.817879
               
           4      .8846513   .2456491    -0.44   0.659     .5131355    1.525149
           3      .4331268   .2024168    -1.79   0.074     .1731865    1.083218
           2       .947312   .3374327    -0.15   0.879     .4710477    1.905115
    education  
               
     2.income     .5332061    .128739    -2.60   0.009     .3320645    .8561853
               
           3      1.802089   .6347407     1.67   0.095     .9030966    3.595986
           2      1.427671   .3463411     1.47   0.142     .8871094    2.297625
   employment  
               
           6       .584252    .243587    -1.29   0.198     .2578975    1.323589
           5      .9751693   .3471448    -0.07   0.944     .4851052    1.960307
           4      1.431255   .7613424     0.67   0.500     .5041793     4.06302
           3      1.295317   .4682546     0.72   0.474     .6374338     2.63219
           2       .482835    .257615    -1.36   0.173     .1695503    1.374988
     dhh_mari  
               
  2.dhhxx_sex     .3897629   .0912629    -4.02   0.000     .2462298    .6169648
               
           3      6.973637   4.528897     2.99   0.003     1.950937    24.92731
           2      6.254813   3.807976     3.01   0.003     1.894975    20.64549
       agecat  
                                                                               
        heart   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
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        _cons     .0062792   .0089992    -3.54   0.000     .0003777    .1044023
               
           4      1.538192    2.13933     0.31   0.757     .1005288    23.53587
           3      5.409362   3.274726     2.79   0.005     1.649946    17.73464
           2      1.853125   1.462362     0.78   0.434     .3941889    8.711739
          a1c  
               
           4      .1704492   .1072632    -2.81   0.005     .0496074    .5856572
           3      .0934909    .087449    -2.53   0.011     .0149278    .5855193
           2      .0554038   .0496742    -3.23   0.001     .0095458    .3215652
   checkingbp  
               
           4      1.958923   1.597458     0.82   0.410     .3957093    9.697468
           3      .5249936   .4363798    -0.78   0.438     .1028281    2.680378
           2      .2462401   .1613772    -2.14   0.033     .0680934    .8904566
   checkingbs  
               
    2.insulin     1.178506   .6684971     0.29   0.772     .3873857    3.585253
               
           3      7.751129   5.655912     2.81   0.005      1.85268    32.42869
           2      2.937472   2.318115     1.37   0.172      .624822    13.80992
      faindex  
               
           5      .7842825   .8284669    -0.23   0.818     .0987784     6.22706
           4      .2348671   .3160448    -1.08   0.282      .016772    3.288974
           3      1.107974    .981067     0.12   0.908     .1951084    6.291923
           2      3.029305   3.490407     0.96   0.336      .316128     29.0284
    typeofsmk  
               
2.durationofd     .3787134    .239754    -1.53   0.125     .1094068    1.310923
     2.income     .7338279   .4632238    -0.49   0.624      .212759    2.531049
               
           3       2.07219   2.049696     0.74   0.461     .2977525    14.42128
           2      1.529652   .9229869     0.70   0.481      .468389    4.995497
   employment  
               
           3      2.728036   2.754324     0.99   0.320      .376548    19.76422
           2       2.19613   1.790279     0.97   0.335     .4438698    10.86577
       agecat  
                                                                               
       bloods   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
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        _cons     .0107163   .0155736    -3.12   0.002     .0006199    .1852455
               
           4      .5269642   .3931964    -0.86   0.391     .1219837    2.276462
           3      .6907901   .5734619    -0.45   0.656     .1356209    3.518565
           2       .321872   .2883969    -1.27   0.206     .0555374    1.865439
   checkingbp  
               
           4      1.476241   1.008537     0.57   0.569     .3866445    5.636408
           3      .9795668   .6526233    -0.03   0.975     .2652273    3.617845
           2      .5430401   .2324655    -1.43   0.154     .2345559    1.257238
   checkingbs  
               
    2.insulin     2.942547   1.023974     3.10   0.002     1.487135    5.822322
               
           3      3.745799   2.361827     2.09   0.036     1.087781    12.89874
           2       1.33046   .8427421     0.45   0.652     .3841791    4.607549
      faindex  
               
           5       .943291   .4811171    -0.11   0.909     .3469425    2.564684
           4      1.307075   .8148049     0.43   0.668     .3849325    4.438301
           3      1.041012   .4565475     0.09   0.927     .4404987    2.460178
           2      .6608218   .4618987    -0.59   0.553     .1677974    2.602457
    typeofsmk  
               
   2.bmiclass     .8173267   .3056022    -0.54   0.590     .3926009    1.701532
2.durationofd     2.040417   .9596319     1.52   0.130     .8112733    5.131812
               
           4      2.868373   1.506772     2.01   0.045     1.023876    8.035706
           3       1.68781   1.094193     0.81   0.420     .4733593    6.018052
           2      .9406791   .5979282    -0.10   0.923      .270451    3.271858
    education  
               
     2.income     .7856904    .295536    -0.64   0.521     .3757476    1.642883
               
           3      2.840862   1.313701     2.26   0.024     1.147124    7.035416
           2      1.509817    .681657     0.91   0.362     .6228854    3.659657
   employment  
               
           6       1.20419   .4827896     0.46   0.643      .548578    2.643333
           5      .4365606    .250395    -1.45   0.149     .1417609    1.344413
           4      1.275401   .8131359     0.38   0.703     .3653084    4.452805
           3      .6596821    .464653    -0.59   0.555     .1657491    2.625538
           2      .0851084   .0654939    -3.20   0.001     .0188183    .3849154
     dhh_mari  
               
  2.dhhxx_sex     .6040612    .198801    -1.53   0.126     .3168028    1.151789
               
           3       .554501    .331508    -0.99   0.324     .1716842    1.790913
           2      1.270189   .5891569     0.52   0.606     .5114856    3.154303
       agecat  
                                                                               
       footul   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
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       _cons     .0403943   .0395193    -3.28   0.001     .0059207    .2755899
              
          4      21.04865   20.59978     3.11   0.002     3.083156    143.6988
          3      2.414281   .7694865     2.77   0.006     1.291535    4.513042
          2      1.542258   .4734416     1.41   0.159     .8442779     2.81727
         a1c  
              
          4      .4851566   .2354007    -1.49   0.136     .1871929    1.257403
          3      1.213566   .6720606     0.35   0.727     .4092695    3.598468
          2      .8283525   .4244039    -0.37   0.713      .303031    2.264348
  checkingbp  
              
          4      .7099511   .3620005    -0.67   0.502     .2609699    1.931374
          3      1.637246   .7755113     1.04   0.298     .6461835    4.148317
          2      .9346287    .286793    -0.22   0.826     .5117714    1.706877
  checkingbs  
              
   2.insulin     2.263865   .7091838     2.61   0.009     1.224118    4.186755
              
          3      .8923078   .3282085    -0.31   0.757     .4334935    1.836736
          2      .9341652   .3614634    -0.18   0.860     .4371149    1.996419
     faindex  
              
          5      .4904653   .2063547    -1.69   0.091     .2147697    1.120066
          4       .991505   .4881033    -0.02   0.986     .3772834    2.605687
          3        1.0011   .3670271     0.00   0.998      .487489    2.055844
          2      1.085851   .9541717     0.09   0.925     .1935236     6.09266
   typeofsmk  
              
  2.bmiclass     2.084941    .712767     2.15   0.032     1.065826    4.078508
2.duration~d     1.563561   .4018977     1.74   0.082      .944087    2.589509
    2.income     .6623789   .1904066    -1.43   0.152     .3767686    1.164497
              
          3      1.592786   .6325074     1.17   0.241     .7305672    3.472599
          2      1.091899   .3369329     0.28   0.776     .5958695    2.000848
  employment  
              
          6      .6635678   .2884176    -0.94   0.346     .2827414    1.557332
          5      1.146092   .4514684     0.35   0.729     .5289799     2.48313
          4      3.089096   2.727093     1.28   0.202      .546155    17.47217
          3      .4752015   .3504112    -1.01   0.313      .111768    2.020404
          2       .671297   .3935027    -0.68   0.497      .212446    2.121196
    dhh_mari  
              
          3      12.74941   8.722726     3.72   0.000     3.328904     48.8291
          2      5.121672   2.945228     2.84   0.005      1.65666    15.83398
      agecat  
                                                                              
       erect   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                           Linearized
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        _cons     .5226087   .3556053    -0.95   0.340      .137576    1.985229
               
           4      1.959433   1.530788     0.86   0.389     .4232844    9.070449
           3      1.206754   .2613413     0.87   0.386     .7891104    1.845439
           2      .9990177   .2131272    -0.00   0.996     .6574195    1.518112
          a1c  
               
           4       .148194    .059541    -4.75   0.000     .0673872    .3258997
           3      .3091675   .1391557    -2.61   0.009     .1278729    .7474964
           2      .7709241   .3397883    -0.59   0.555     .3247548     1.83007
   checkingbp  
               
           4        1.3292   .4537855     0.83   0.405     .6804115    2.596625
           3       1.23736   .4548764     0.58   0.562     .6016459    2.544786
           2      1.257681   .2655555     1.09   0.278     .8311998    1.902987
   checkingbs  
               
    2.insulin     1.021217   .2320627     0.09   0.926     .6539474    1.594752
               
           3      1.298407   .3422031     0.99   0.322     .7742851    2.177312
           2      1.394248   .4084652     1.13   0.257     .7848358     2.47686
      faindex  
               
           5      1.314753   .3664172     0.98   0.326     .7610916    2.271179
           4      1.714059   .5736641     1.61   0.108     .8890535    3.304637
           3      1.272161   .3328897     0.92   0.358     .7614421    2.125433
           2      1.493868   1.001023     0.60   0.549     .4013276    5.560651
    typeofsmk  
               
   2.bmiclass     2.843595   .6323794     4.70   0.000     1.838347    4.398535
2.durationofd     1.445482   .2883419     1.85   0.065     .9774341    2.137655
               
           4      .6105541   .1502664    -2.00   0.045     .3767659    .9894109
           3      .5360111   .1980524    -1.69   0.092     .2596699    1.106435
           2      .8819395   .2797385    -0.40   0.692      .473418    1.642982
    education  
               
     2.income     1.068634   .2145505     0.33   0.741     .7207796    1.584365
               
           3      1.846057   .6361851     1.78   0.075     .9390364    3.629173
           2      1.628294   .3409271     2.33   0.020      1.07988    2.455219
   employment  
               
           6      1.069639   .2965877     0.24   0.808     .6209233    1.842622
           5      1.045438   .2796003     0.17   0.868     .6186905     1.76654
           4      1.378009   .8699544     0.51   0.612     .3994563    4.753731
           3      .5852854   .2025991    -1.55   0.122     .2968224    1.154088
           2      1.053816   .4114717     0.13   0.893     .4899514    2.266608
     dhh_mari  
               
  2.dhhxx_sex     1.468354   .2635673     2.14   0.032     1.032584    2.088028
               
           3      1.375795   .4989032     0.88   0.379     .6755362    2.801939
           2       2.05488   .5984969     2.47   0.014     1.160593    3.638251
       agecat  
                                                                               
       bloodp   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized









                                                                               
        _cons     .0152376    .011348    -5.62   0.000      .003536    .0656626
               
           4      .7898612   .5816735    -0.32   0.749     .1863072    3.348667
           3      .7189532   .1715721    -1.38   0.167     .4502095    1.148118
           2      .6823413   .1744058    -1.50   0.135     .4133047    1.126505
          a1c  
               
           4      .6775741   .2219836    -1.19   0.235     .3563517    1.288353
           3       .454667   .2115093    -1.69   0.090     .1825651     1.13232
           2      .9247067   .3281907    -0.22   0.825     .4609696    1.854965
   checkingbp  
               
           4      1.153348   .3900976     0.42   0.673     .5940729    2.239139
           3      .4913377   .1997461    -1.75   0.081     .2213474    1.090651
           2      .5008152   .1265201    -2.74   0.006     .3051243    .8220119
   checkingbs  
               
    2.insulin     1.708156   .4041993     2.26   0.024      1.07388     2.71706
               
           3      1.722669   .5061788     1.85   0.064     .9680557    3.065515
           2      1.865166   .6100611     1.91   0.057     .9819612    3.542752
      faindex  
               
           5      .8546479   .2746428    -0.49   0.625     .4550348    1.605203
           4      .8364823   .3044963    -0.49   0.624     .4096071    1.708229
           3       .888334   .2775437    -0.38   0.705     .4813183    1.639533
           2      .5207565   .4167997    -0.82   0.415     .1083525    2.502824
    typeofsmk  
               
   2.bmiclass       .74989   .1773513    -1.22   0.224     .4715559     1.19251
2.durationofd     2.896641   .6598797     4.67   0.000     1.852835    4.528482
               
           4       1.63405   .4392409     1.83   0.068     .9644609     2.76851
           3      1.201003   .5248086     0.42   0.675     .5096923    2.829958
           2      .5792116   .2227153    -1.42   0.156     .2724518    1.231359
    education  
               
     2.income     1.101063   .2452265     0.43   0.666     .7113618    1.704252
               
           3       5.37386   2.010076     4.50   0.000     2.580214    11.19224
           2      4.028596   .9815069     5.72   0.000     2.498125    6.496709
   employment  
               
           6      .8956939   .2817457    -0.35   0.726     .4832883    1.660019
           5      1.445928   .4507991     1.18   0.237     .7844497     2.66519
           4      2.085998   1.282468     1.20   0.232     .6245975    6.966709
           3      2.604169   .8563659     2.91   0.004     1.366295    4.963569
           2      .5889595   .3311217    -0.94   0.347      .195508    1.774215
     dhh_mari  
               
  2.dhhxx_sex     1.892331    .397075     3.04   0.002     1.253865    2.855902
               
           3      8.153526   4.030672     4.24   0.000     3.091986    21.50074
           2      2.758459   1.253743     2.23   0.026     1.131084    6.727256
       agecat  
                                                                               
       catara   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized








                                                                               
        _cons      .012865    .010782    -5.19   0.000     .0024868    .0665564
               
           4      1.270966   .5449804     0.56   0.576      .548204    2.946631
           3       .653125   .3314053    -0.84   0.401     .2414591    1.766644
           2      1.056441   .5285082     0.11   0.913     .3960737     2.81783
   checkingbp  
               
           4      1.009976   .4183492     0.02   0.981     .4482632    2.275566
           3      .5551698   .3177659    -1.03   0.304     .1806955    1.705707
           2      .7888641   .2641654    -0.71   0.479     .4090754    1.521251
   checkingbs  
               
    2.insulin     1.360267   .4237525     0.99   0.323     .7384294    2.505759
               
           3      1.095197   .4497366     0.22   0.825     .4895047    2.450349
           2      .9973625   .4311615    -0.01   0.995     .4272405    2.328272
      faindex  
               
           5      .9641649      .3579    -0.10   0.922     .4655943    1.996618
           4      1.354784   .6933544     0.59   0.553     .4965897    3.696088
           3      1.060293   .3626409     0.17   0.864      .542171    2.073554
           2      .5918808   .3913831    -0.79   0.428     .1618308    2.164748
    typeofsmk  
               
   2.bmiclass     .9805824   .3498432    -0.05   0.956     .4871147    1.973954
2.durationofd     1.694392   .4774933     1.87   0.061     .9750006    2.944576
               
           4      1.262927   .3847215     0.77   0.444     .6949206    2.295205
           3      .3782233   .2527654    -1.45   0.146     .1019944    1.402556
           2      .5970239   .2386057    -1.29   0.197     .2726543    1.307287
    education  
               
     2.income     .4879206   .1710555    -2.05   0.041       .24534    .9703534
               
           3      1.252593   .5474056     0.52   0.606     .5316335    2.951259
           2      1.221146   .3791839     0.64   0.520     .6642166    2.245046
   employment  
               
           6      1.240306   .4468883     0.60   0.550     .6118798    2.514152
           5      1.130521   .4918122     0.28   0.778     .4816958    2.653286
           4      .3493595   .2444013    -1.50   0.133     .0886067    1.377459
           3      1.280514   .4330812     0.73   0.465     .6596902    2.485584
           2      1.951021   1.044436     1.25   0.212     .6828675    5.574262
     dhh_mari  
               
  2.dhhxx_sex     .9946382   .2731257    -0.02   0.984     .5804927    1.704251
               
           3      6.571164   3.679327     3.36   0.001     2.191655     19.7021
           2      3.307979   1.740311     2.27   0.023     1.178964    9.281644
       agecat  
                                                                               
       glauco   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
                                                                               
132 
 







                                                                               
        _cons     .0293548   .0200831    -5.16   0.000     .0076718    .1123207
               
           4      3.805814   3.549962     1.43   0.152     .6107754    23.71448
           3      2.034747   .7076591     2.04   0.041     1.028618    4.025007
           2      .9511401   .4007167    -0.12   0.905     .4162618    2.173314
          a1c  
               
           4       2.41156   1.348187     1.57   0.116     .8055271    7.219648
           3      1.436152   1.279131     0.41   0.685     .2503248    8.239432
           2      2.070697   .8886277     1.70   0.090     .8923965    4.804799
   checkingbs  
               
    2.insulin     2.621129   1.056319     2.39   0.017     1.189047    5.778005
               
           5      1.691216   .7501905     1.18   0.236     .7085051    4.036966
           4      1.558827   .7709038     0.90   0.369     .5909249      4.1121
           3      .8839385   .3695522    -0.30   0.768     .3893077    2.007018
           2      .8490783   .6949308    -0.20   0.842     .1705153    4.227972
    typeofsmk  
               
   2.bmiclass     1.223062   .5238509     0.47   0.638     .5279579    2.833331
2.durationofd     .7232148   .2362359    -0.99   0.321     .3810825     1.37251
     2.income     .7224512   .2574428    -0.91   0.362      .359138    1.453301
               
           3      2.527197   1.267918     1.85   0.065     .9446422    6.761001
           2      1.235314   .5096178     0.51   0.609     .5499985    2.774552
   employment  
               
           6      .7376813   .4084491    -0.55   0.583     .2490091    2.185356
           5      .6579824   .2620068    -1.05   0.293     .3013126     1.43685
           4      .2106749   .1941279    -1.69   0.091      .034569    1.283924
           3      1.694137   .8543253     1.05   0.296     .6300629     4.55526
           2      .8054587   .5108395    -0.34   0.733      .232163    2.794432
     dhh_mari  
               
  2.dhhxx_sex     1.674816   .5029592     1.72   0.086     .9293001     3.01841
               
           3       .356797   .2445986    -1.50   0.133     .0929943    1.368944
           2      .6437618   .3370718    -0.84   0.400       .23052    1.797802
       agecat  
                                                                               
         gums   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized








                                                                               
        _cons     .0021487   .0025115    -5.26   0.000      .000217    .0212743
               
           4      .7855181   .8330323    -0.23   0.820     .0981251    6.288286
           3      .8866676   .2956122    -0.36   0.718     .4610594    1.705159
           2      1.092979   .4359926     0.22   0.824      .499812    2.390106
          a1c  
               
           4       1.93037   1.015613     1.25   0.211     .6878007    5.417745
           3      1.629689    1.06422     0.75   0.455       .45272    5.866509
           2      1.548699   .9715468     0.70   0.486     .4524548     5.30101
   checkingbp  
               
           4       2.22188   1.788257     0.99   0.321     .4582668    10.77266
           3      .1828883   .1882773    -1.65   0.099     .0242793    1.377642
           2      1.002723   .3544913     0.01   0.994     .5012196    2.006016
   checkingbs  
               
    2.insulin     11.34252   4.096813     6.72   0.000     5.585083    23.03508
               
           3      .9167003   .4129726    -0.19   0.847     .3788524    2.218119
           2       .869904   .4185066    -0.29   0.772     .3385717    2.235075
      faindex  
               
           5      2.688311   1.526284     1.74   0.082     .8827616    8.186825
           4      5.870324   3.622452     2.87   0.004     1.749862    19.69339
           3      1.824413   .9668756     1.13   0.257     .6451672    5.159099
           2      .9781541    .836863    -0.03   0.979     .1826437    5.238537
    typeofsmk  
               
   2.bmiclass     .5037263   .2032009    -1.70   0.089     .2283297    1.111289
2.durationofd     8.006247   3.328732     5.00   0.000     3.542079    18.09672
               
           4      1.747188   .8558925     1.14   0.255      .668414    4.567031
           3      1.003287   .7097001     0.00   0.996     .2505235    4.017929
           2      .4060376   .2604527    -1.41   0.160     .1153845    1.428844
    education  
               
     2.income     .4822504   .1615773    -2.18   0.030     .2499549    .9304297
               
           3      .3955702   .2344598    -1.56   0.118     .1236861    1.265104
           2      .4329357   .1556322    -2.33   0.020     .2138945    .8762885
   employment  
               
           6      1.223042    .466256     0.53   0.597     .5790205    2.583385
           5      .4195624   .2010872    -1.81   0.070      .163879    1.074162
           4      .1033784   .1435502    -1.63   0.102     .0067852    1.575067
           3      1.140794   .5750441     0.26   0.794     .4244361    3.066211
           2      .4815595   .3510824    -1.00   0.316     .1152409    2.012303
     dhh_mari  
               
  2.dhhxx_sex     .7525321   .2755883    -0.78   0.438     .3669148    1.543422
               
           3      3.309996   2.078915     1.91   0.057     .9656165    11.34619
           2      1.777648   .8331606     1.23   0.220     .7089165    4.457555
       agecat  
                                                                               
       retino   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
                                                                               
134 
 





                                                                               
        _cons     .6047881   .4440107    -0.68   0.493     .1432844    2.552747
               
           4      5.173627   5.311115     1.60   0.110     .6907039    38.75237
           3      2.614374   .7737057     3.25   0.001     1.463067     4.67166
           2      1.336133   .4082189     0.95   0.343     .7338134    2.432841
          a1c  
               
           4      .3181038   .1532588    -2.38   0.018     .1236375    .8184415
           3      .3541603   .1868458    -1.97   0.049     .1258282    .9968317
           2       .417405   .2236806    -1.63   0.103     .1459005    1.194148
   checkingbp  
               
           4      1.321705    .570874     0.65   0.519     .5664932    3.083714
           3      .6302865   .3418861    -0.85   0.395      .217501     1.82648
           2      .6381917   .1995475    -1.44   0.151     .3456153    1.178445
   checkingbs  
               
    2.insulin     2.316624   .6428838     3.03   0.003     1.344174    3.992599
               
           3      1.224422    .392708     0.63   0.528     .6526996    2.296938
           2      .8397576   .3078992    -0.48   0.634     .4090868    1.723822
      faindex  
               
           5      1.075677   .4002615     0.20   0.845     .5184435    2.231837
           4      .7369259   .3317407    -0.68   0.498     .3047483    1.781995
           3      .8844054   .3039052    -0.36   0.721     .4507419    1.735301
           2      2.215961     1.8874     0.93   0.350     .4168725    11.77934
    typeofsmk  
               
   2.bmiclass     .9161754   .2543497    -0.32   0.753      .531475    1.579335
2.durationofd     1.207283   .3123399     0.73   0.467     .7268095    2.005385
               
           4      1.243823   .4837037     0.56   0.575     .5800712    2.667079
           3       1.33807   .7699685     0.51   0.613     .4328011    4.136846
           2      .5178696   .2586661    -1.32   0.188     .1944151    1.379466
    education  
               
     2.income       .68715    .178159    -1.45   0.148     .4132249    1.142659
               
           3      .4584809   .1916043    -1.87   0.062     .2019841    1.040699
           2      .5255493   .1301751    -2.60   0.009     .3233048    .8543088
   employment  
               
           6       1.34747   .4809101     0.84   0.404     .6690982    2.713617
           5       .777659    .336162    -0.58   0.561      .333081    1.815635
           4        .52745   .2975313    -1.13   0.257     .1744413    1.594826
           3      1.374185   .6372237     0.69   0.493     .5533839     3.41243
           2      1.782917   .8413225     1.23   0.221     .7065672    4.498928
     dhh_mari  
               
  2.dhhxx_sex     .8040344   .1923707    -0.91   0.362      .502875    1.285551
               
           3      .7809696   .3740723    -0.52   0.606     .3052137    1.998316
           2      .5023271   .1694479    -2.04   0.041     .2591974    .9735151
       agecat  
                                                                               
     proteinu   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
                                                                               
135 
 
B.12 )Poor Circulation 
 
 . 
                                                                               
        _cons     .1528465    .109009    -2.63   0.009     .0377331    .6191395
               
           4      2.798363    2.30986     1.25   0.213      .554319    14.12695
           3      1.370716   .3668594     1.18   0.239     .8108822    2.317059
           2        .60028   .1760766    -1.74   0.082     .3376648    1.067141
          a1c  
               
           4       .748854    .322938    -0.67   0.503      .321398    1.744822
           3      .5413133   .2639047    -1.26   0.208     .2080411    1.408472
           2      .7019195   .3241182    -0.77   0.443      .283751     1.73635
   checkingbp  
               
           4      1.038201   .4122406     0.09   0.925       .47647     2.26218
           3      .7317763   .3323347    -0.69   0.492     .3002705    1.783381
           2      .9712389   .2565135    -0.11   0.912     .5785548    1.630451
   checkingbs  
               
    2.insulin     2.474475   .5867089     3.82   0.000     1.554196    3.939675
               
           3      2.080994   .6602297     2.31   0.021     1.116883    3.877343
           2      1.425667   .4772929     1.06   0.290     .7393172    2.749192
      faindex  
               
           5      .6023312   .1891178    -1.61   0.107     .3253679    1.115054
           4       .665556   .3557486    -0.76   0.446     .2332704    1.898933
           3      .9289236   .2700183    -0.25   0.800     .5252493    1.642837
           2      .3789829   .2443592    -1.50   0.133     .1069959     1.34237
    typeofsmk  
               
   2.bmiclass     1.129223   .3159753     0.43   0.664     .6522565    1.954976
2.durationofd     1.093695   .2558717     0.38   0.702     .6912015    1.730565
               
           4      1.335132   .3796436     1.02   0.310     .7643665    2.332098
           3      .8491447   .3472816    -0.40   0.689     .3807096    1.893954
           2      1.142699   .3964463     0.38   0.701     .5786186    2.256687
    education  
               
     2.income     .5027611    .118854    -2.91   0.004     .3162148    .7993577
               
           3      2.182393   .7197562     2.37   0.018     1.142857    4.167486
           2      1.164316   .2829643     0.63   0.531     .7228455     1.87541
   employment  
               
           6      1.005447   .3355138     0.02   0.987     .5225167     1.93472
           5      .8972163   .3069856    -0.32   0.751     .4585999    1.755336
           4      .8725009   .4701441    -0.25   0.800     .3032143    2.510626
           3      1.248248   .4160338     0.67   0.506     .6492086    2.400034
           2      .6187853   .2468344    -1.20   0.229     .2829671    1.353144
     dhh_mari  
               
  2.dhhxx_sex     .9513082   .1970627    -0.24   0.810     .6336674    1.428174
               
           3      1.274559    .546276     0.57   0.571     .5498664    2.954355
           2      1.296216   .4595643     0.73   0.464     .6466366    2.598333
       agecat  
                                                                               
    poorcircu   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized








                                                                               
        _cons     .0308495   .0355531    -3.02   0.003     .0032175    .2957862
               
           4      2.597557    1.91264     1.30   0.195     .6128148    11.01035
           3       1.28134   .4548146     0.70   0.485     .6387026    2.570575
           2      1.303842     .45205     0.77   0.444     .6605162    2.573749
          a1c  
               
           4      .6303423   .3446499    -0.84   0.399      .215682    1.842209
           3      .7478069   .5080685    -0.43   0.669     .1972575    2.834951
           2      .4930191   .2917325    -1.20   0.232      .154455    1.573713
   checkingbp  
               
           4      .6196259   .3184769    -0.93   0.352     .2260966    1.698107
           3      .2332809   .1549646    -2.19   0.029     .0633884    .8585159
           2      .6413193   .2033034    -1.40   0.161     .3443746    1.194311
   checkingbs  
               
    2.insulin     2.602075   .8432073     2.95   0.003     1.378086    4.913185
               
           3      1.956199   .8099271     1.62   0.105     .8684024    4.406614
           2        1.1672   .5200071     0.35   0.729     .4871161     2.79678
      faindex  
               
           5      .7256838   .2917631    -0.80   0.425     .3298065    1.596745
           4      1.027005   .5745027     0.05   0.962     .3428085    3.076761
           3      1.236178   .4521513     0.58   0.562     .6032595    2.533134
           2      .7452733   .4838594    -0.45   0.651     .2085754    2.662981
    typeofsmk  
               
   2.bmiclass     1.623092   .5623302     1.40   0.162     .8226492     3.20237
2.durationofd     1.333586   .4065554     0.94   0.345     .7333768    2.425017
               
           4      1.808178   .8064498     1.33   0.184     .7539029    4.336777
           3      1.443297   .8952202     0.59   0.554     .4275505    4.872189
           2      1.631754   .8339625     0.96   0.338     .5988093    4.446525
    education  
               
     2.income     .8187825   .2409846    -0.68   0.497     .4596759    1.458429
               
           3      3.882094   1.571943     3.35   0.001     1.754422    8.590097
           2      2.751617   .8438227     3.30   0.001     1.507843    5.021341
   employment  
               
           6      .6543146   .2492446    -1.11   0.266     .3099533    1.381265
           5      .7960927   .3493735    -0.52   0.603     .3366052     1.88281
           4      4.602436   3.341256     2.10   0.036     1.108067    19.11655
           3      .8003652   .3830821    -0.47   0.642     .3130142    2.046503
           2      .8774091   .5195951    -0.22   0.825     .2746271    2.803243
     dhh_mari  
               
  2.dhhxx_sex     .5472388   .1625191    -2.03   0.043      .305629    .9798491
               
           3      .4541736   .2262524    -1.58   0.113     .1709474     1.20665
           2      .7170818   .2951371    -0.81   0.419     .3198629    1.607583
       agecat  
                                                                               
       neurop   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
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        _cons     .1896787   .2321886    -1.36   0.175     .0171893    2.093044
               
           4      2.497042   2.516633     0.91   0.364     .3458554    18.02839
           3      1.066801   .4295797     0.16   0.872     .4842406    2.350204
           2      .3552239   .1891772    -1.94   0.052     .1249811    1.009625
          a1c  
               
           4      .1670852   .0907511    -3.29   0.001     .0575789    .4848558
           3      .0613215    .054127    -3.16   0.002      .010857    .3463517
           2      .2732251   .1773443    -2.00   0.046     .0764901    .9759686
   checkingbp  
               
           4      .6981447   .3802524    -0.66   0.510     .2398706    2.031954
           3      .6099016   .7084248    -0.43   0.670     .0624892    5.952705
           2      .2431944   .1398917    -2.46   0.014     .0786953    .7515509
   checkingbs  
               
    2.insulin     1.086128   .6108676     0.15   0.883     .3603951    3.273279
               
           3      1.921582   1.576213     0.80   0.426     .3845167    9.602903
           2      1.337542   1.224071     0.32   0.751     .2221913     8.05171
      faindex  
               
           5      .4358199   .3614544    -1.00   0.317     .0856669    2.217179
           4      .4305309    .360264    -1.01   0.314      .083404    2.222398
           3      .7099001   .3981687    -0.61   0.541     .2362724    2.132954
           2      1.114118   1.204238     0.10   0.920     .1337144    9.282908
    typeofsmk  
               
   2.bmiclass     .6274438   .2653353    -1.10   0.271      .273743    1.438158
2.durationofd     1.344275   .6221396     0.64   0.523     .5423096    3.332184
               
           4       1.10762   .5291752     0.21   0.831     .4339237    2.827278
           3       .014207   .0174825    -3.46   0.001     .0012713    .1587617
           2      1.969326   1.253726     1.06   0.287     .5649479    6.864784
    education  
               
     2.income     .2499758   .1022561    -3.39   0.001     .1120566    .5576456
               
           3      2.421464   1.298548     1.65   0.099      .845788    6.932577
           2      1.628372   .7963417     1.00   0.319     .6239717    4.249546
   employment  
               
           6      .5954479   .3246262    -0.95   0.342     .2043778    1.734818
           5      .3068582   .1934137    -1.87   0.061     .0891283    1.056477
           4      5.118323   3.288763     2.54   0.011     1.451362     18.0501
           3      2.225799     1.3516     1.32   0.188     .6764061    7.324268
           2      2.362052   1.517624     1.34   0.181     .6698466    8.329206
     dhh_mari  
               
  2.dhhxx_sex     .3352624   .1212646    -3.02   0.003     .1649191    .6815514
               
           3      1.397442   1.468501     0.32   0.750     .1778976    10.97734
           2      2.883788   2.640548     1.16   0.248     .4785937     17.3764
       agecat  
                                                                               
       kidney   Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval]
                            Linearized
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Appendix C. Search Strategy 
•  MEDLINE  
1. Diabetes mellitus / or exp diabetes mellitus, type 2/ 
2. (diabet# or DM) adj2 (“type 2” or “type ii”)).mp. 
3. (diabet# adj2 (“type 1” or “type I”)).mp. 
4. T2DM.ti,ab 
5. NIDDM.ti,ab 
6. 1 or 2 or 3 or 4 or 5 
7. Exp pharmaceutical service/ 
8. Exp Clinical pharmacy/ 
9. Exp Community pharmacy/ 
10. Exp Pharmacy based intervention/ 
11. Exp Pharmacist/ 
12. 7 or 8 or 9 or 10 or 11 
13. 6 AND 12  
• EMBASE 
Same MESH, keywords and limits will be used as per MEDLINE search, with appropriate syntax used 
• COCHRANE 
Same MESH, keywords and limits will be used as per MEDLINE search, syntax adjusted for Cochrane library database 
• CINHAL 
Same keyword used peer MEDLINE search  







Databases N of Results 
Ovid MEDLINE<1946 to Present> 326 
EBM Reviews - Cochrane Central Register of Controlled Trials < February 2017> 274 
CINAHL  205 
Embase <1974 to 2017 February > 146 
Total Results (Including Duplicate Records) 951 
Total Results (Excluding 361 Duplicate Records Found by EndNote X4) 590 
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Appendix D. Estimating the progression from diabetes with no complication to diabetes-related 
complication state 
Table D.1. Risk equation for developing four diabetes-related complications based on UKPDS study 
Risk equation for developing complications Mean Se Functional form Source 
Stroke *     
λ -13.053 1.41 Weibull Hayes AJ (2013) 
P 1.466 0.15 Weibull Hayes AJ (2013) 
Age of Diagnoses  0.666 0.01 Weibull Hayes AJ (2013) 
Sex -0.42 0.19 Weibull Hayes AJ (2013) 
HbA1c 0.092 0.05 Weibull Hayes AJ (2013) 
Smoke 0.331 0.21 Weibull Hayes AJ (2013) 
Heart Failure history 0.481 0.27 Weibull Hayes AJ (2013) 
Amputation history 1.09 0.47 Weibull Hayes AJ (2013) 
LDL 0.016 0.007 Weibull Hayes AJ (2013) 
ATFIB 1.467 0.39 Weibull Hayes AJ (2013) 
MMALB 0.42 0.19 Weibull Hayes AJ (2013) 
SBP 0.17 0.04 Weibull Hayes AJ (2013) 
WBC 0.04 0.01 Weibull Hayes AJ (2013) 
Heart Failure *     
λ -12.332 1.6 Weibull Hayes AJ (2013) 
P 1.514 0.17 Weibull Hayes AJ (2013) 
Age of Diagnoses  0.068 0.01 Weibull Hayes AJ (2013) 
BMI 0.072 0.01 Weibull Hayes AJ (2013) 
Amputation History 0.0658 0.64 Weibull Hayes AJ (2013) 
Ulcer foot History 0.654 0.57 Weibull Hayes AJ (2013) 
ATFIB 1.562 0.48 Weibull Hayes AJ (2013) 
LDL 0.012 0.009 Weibull Hayes AJ (2013) 
MMALB 0.771 0.22 Weibull Hayes AJ (2013) 
PVD 0.479 0.26 Weibull Hayes AJ (2013) 
Amputation*     
λ -14.844 2.36 Weibull Hayes AJ (2013) 
P 2.067 0.37 Weibull Hayes AJ (2013) 
Age of Diagnoses  0.023 0.02 Weibull Hayes AJ (2013) 
Sex -0.445 0.37 Weibull Hayes AJ (2013) 
HbA1c 0.248 0.08 Weibull Hayes AJ (2013) 
Stroke History 1.299 0.47 Weibull Hayes AJ (2013) 
ATFIB 1.088 0.78 Weibull Hayes AJ (2013) 
HDL -0.059 0.06 Weibull Hayes AJ (2013) 
MMALB 0.602 0.35 Weibull Hayes AJ (2013) 
PVD 1.01 0.37 Weibull Hayes AJ (2013) 
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SBP 0.086 0.07 Weibull Hayes AJ (2013) 
WBC 0.04 0.01 Weibull Hayes AJ (2013) 
Heart rate 0.098 0.09 Weibull Hayes AJ (2013) 
Blindness     
λ -11.607 1.48 Exponential Hayes AJ (2013) 
Age of Diagnoses  0.047 0.01 Exponential Hayes AJ (2013) 
HbA1c 0.171 0..06 Exponential Hayes AJ (2013) 
Heart Failure History 0.841 0.54 Exponential Hayes AJ (2013) 
Stroke History 0.61 0.39 Exponential Hayes AJ (2013) 
SBP 0.068 0.06 Exponential Hayes AJ (2013) 
WBC 0.052 0.03 Exponential Hayes AJ (2013) 
Heart rate 0.08 0.05 Exponential Hayes AJ (2013) 
 
Following descriptions derived from the supplementary material of United Kingdom Prospective 
Diabetes model (UKPDS2) (1)  
The Weibull model of UKPDS for heart failure in table D.1 assumes a baseline hazard given by: 
𝐻0 (𝑡) = 𝑃𝑡𝑝−1 exp(𝜆) 
And in the proportional hazards model; 
ℎ(𝑡|𝑥𝑗) = ℎ0(𝑡)exp (𝛽𝑗𝑥𝑗) =𝑃𝑡𝑝−1 exp(𝜆 + 𝛽𝑗𝑥𝑗) 
The parameters requiring calculation are λ, βj and p, which are given in Table D.1; time at risk (t) in the 
model is duration of diabetes. The unconditional probability of heart failure occurring between time t 
and t+1 can be estimated using the integrated hazard. The integrated hazard at time t is: 
ℎ(𝑡|𝑥𝑗) = exp(𝜆 + 𝛽𝑗𝑥𝑗) 𝑡𝑝  
And the unconditional probability of heart failure in the interval t to t+1 is: 
1 − exp {(H(t|𝑥𝑗) − 𝐻(𝑡 + 1|𝑥𝑗)} 
For example the calculation of the probability of heart failure in the current year for a one patient 
record in SLCDC with following characteristic (male, 70 years of age, with 8 years of diabetes, LDL 3.0 
mmol/l, BMI of 32, eGFR 50, with microalbuminuria and a history of amputation) estimated as below: 
t1= 8 years diabetes 
H (t1|xj) = exp (-12.332 + 0.068*62 + 3*10*0.012 + 0.072* 32 + (50/10)*-0.22 + 0.771 +0.658) * 8 1.514 
= 0.1388 
t2= 9 years diabetes 
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H (t2|xj) = exp (-12.332 + 0.068*62 + 3*10*0.012 + 0.072* 32 + (50/10)*-0.22 + 0.771 +0.658) * 9 1.514 
= 0.1659 
























Appendix E. Estimating the Probability of death in the 1st year of complication/s and no history of 
events  




Following descriptions derived from the supplementary material of United Kingdom Prospective 
Diabetes model (UKPDS2) (1)  
Probability of death in the 1st year of complication/s and no history of events:  







z = 𝜆 + 𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥3 + ⋯ 𝛽𝑛𝑥𝑛 
Current year MI 
As an example, using the coefficients in Table E.1, for a one patient record in SLCDC with following 
characteristic (70 year-old male smoker with 12 years of diabetes, heart rate 80 bpm, has an MI but has 
no history of other events)  
z= (-6.916 +0.058*70 + 0.042*12 +0.124*80/10 +0.444 + 1.309) = 0.393 
Probability of survival = exp (-0.393)/ (1+ exp (-0.393)) =0.403 
Probability of death in current year = 0.597 
Current year heart failure 
Similarly, the same person with heart failure 
z= (-6.916 +0.058*70 + 0.042*12 +0.124*80/10 +0.444) = -0.916 
Probability of survival = exp (0.916)/(1+ exp (0.916)) =0.714 
Probability of death in current year = 0.286 
Also Gompertz regression model was used, in which the hazard of death increases exponentially with 
age. The Gompertz model assumes a baseline hazard given by: 
 
𝐻0 (𝑡) = exp(ɸ𝑡) exp(𝜆) 
and in the proportional hazards model 




The parameters required are λ, βj and ɸ, which are given in table E.1; time at risk (t) in the model is 
current age. The probability of death occurring between time t and t+1 can be estimated using the 
integrated hazard. The integrated hazard at time t is: 
ℎ(𝑡|𝑥𝑗) = ɸ−1 exp(𝜆 + 𝛽𝑗𝑥𝑗){exp(ɸ𝑡) − 1} 
And the unconditional probability of death in the interval t to t+1 is: 
1 − exp {(H(t|𝑥𝑗) − 𝐻(𝑡 + 1|𝑥𝑗)} 
As an example, using the coefficients in Table E, for a patient record in SLCDC with following 
characteristics (a 70 year-old male smoker with 12 years of diabetes, who is overweight, has a white 
blood cell count of 6x106/ml and a history of heart failure but no events in the current year) 
t1=70 years; t2=71 years 
 
H (t1|xj) = 0.073−1  exp (-9.207-0.293 +0.374 +0.048*6 + 0.632) { exp (0.073*70)-1} 
= 0.6201 
H (t2|xj) = 0.073−1  exp (-9.207-0.293 +0.374 +0.048*6 + 0.632) { exp (0.073*71)-1} 
= 0.6674 
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